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A bstract
Metachromatic leukodystrophy (MLD) is a lysosomal storage disease caused by
a mutation in the enzyme, arylsulfatase A (ASA) and is characterized by progressive
and fatal demyelination in the central and peripheral nervous systems. To date, no
effective treatment exists and development is hampered by the blood-brain barrier
(BBB). I have successfully generated fusion proteins using an ApoE fragment as a
molecular Trojan horse fused to the full-length human ASA. These proteins were
expressed in eukaryotic cells transduced with lentiviral expression vectors and have
been assessed for in vitro enzymatic activity and kinetic properties. Although preliminary
studies show that these constructs did not cross an in vitro BBB model under these
experimental conditions, there is evidence to suggest that the ApoE fragment facilitates
the uptake of fusion proteins into the endothelial cells of the BBB. Recommendations for
further study are encouraged to reach the goal to find treatment for MLD.

Keywords: MLD, ASA, molecular Trojan horse, ApoE, fusion protein, blood brain
barrier
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Chapter 1 - Introduction

1.1 M etachrom atic leukodystrophy
Metachromatic leukodystrophy (MLD; OMIM 250100) is an autosomal
recessive lysosomal storage disease caused by a mutation in the gene encoding
the enzyme, arylsulfatase A (ASA; EC 3.1.6.8). To date, there have been more
than 100 MLD-causing mutations described with the majority of defective ASA
alleles containing missense mutations. (1) Pathological hallmarks of this
neurodegenerative disease include the presence of metachromatic granules in
lysosomal vesicles, reduced numbers of oligodendrocytes, and the progressive
demyelination of the central (CNS) and peripheral nervous systems (PNS).
Clinically, there are three subtypes of disease that are distinguishable by the age
of onset. Late infantile metachromatic leukodystrophy generally manifests
between 1 >2 - 2 years of age; the onset of juvenile MLD occurs between the
ages of 4 and 16; and patients presenting after the age of 16 are diagnosed with
the adult form of the disease (2, 3).
The most frequently occurring form of this disease is late infantile MLD,
accounting for approximately 50% of diagnosed cases with an estimated
frequency as high as 1 in 40,000 newborns (4, 5). The focus of this paper will be
on the infantile form of MLD, hereafter referred to simply as MLD. Affected infants
typically exhibit normal development for the first year but begin to present with a
loss of age-related milestones, often beginning with gait difficulties followed by
other symptoms that include mental regression, aphasia, feeding and breathing
difficulties, and blindness, leading to a decerebrated state. To date, there is no
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effective treatment for this disease and death generally occurs within 5 years. (2,
6)
1.2 Arylsulfatase A
The gene encoding ASA has been mapped to the long arm of
chromosome 22 in the human genome. It is a relatively small gene (3.2 kb)
composed of 8 exons(7, 8) that encode a 507 amino acid product with an 18
amino acid leader sequence and a 489 amino acid mature enzyme with a
molecular weight of approximately 62kDa. (8)
As with most lysosomal enzymes, ASA follows the mannose-6 phosphate
(M6P) pathway that targets enzymes to the lysosome. Translated at the rough
endoplasmic reticulum, the ASA pre-protein receives several post-translational
modifications including the addition of three N-linked oligosaccharide side chains
and a critical conversion of a cysteine to Ca-formylglycine. These modified
enzymes dimerize and move to the Golgi complex where most are recognized by
mannose 6-phospate receptors (M6PR) that target them to lysosomes. Within the
acidic environment of the lysosome, dimerized proteins further oligomerize into
octomers and act upon their substrate, sulfatide.(9) A small percentage (10-30%)
of the lysosomal enzymes bypass targeting to the lysosome and these diffuse to
extracellular space (6). Here, M6PRs on the plasma membrane of neighbouring
cells can recognize and endocytose the exogenous enzyme which may
subsequently be targeted to lysosomal compartments. (Figure 1.1). (10, 11)
ASA catalyzes the first step in the degradation of the sphingolipid, 3-0sulfogalactosylceramide (sulfatide). Hydrolysis by ASA breaks sulfatide down to
galactocerebroside. This substrate is then enzymatically degraded by
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Figure 1.1 Trafficking of lysosomal enzymes. Lysosomal enzymes are translated
at the rough endoplasmic reticulum and are post-translationally modified. ASA
pre-proteins dimerize and move to the Golgi complex. Most of the pro-enzymes
are then targeted to the lysosomes where, under the low pH conditions, they form
octomers and become active (a). A small percentage of enzyme is secreted to
the extracellular space where it can be picked up by M6PR on neighbouring cells
and targeted to the lysosomes of that cell to be activated (b). Illustration adapted
from Sands and Davidson, 2006.

galactocerebrosidase to ceramide which is in turn broken down into sphingosine
and fatty acid (Figure 1.2) (1). Any disruption along this path can lead to
accumulation of substrate.
The substrate for ASA, sulfatide, is a lipid predominately found as a key
constituent of the myelin sheath synthesized by oligodendrocytes within the
central nervous system and by Schwann cells in the peripheral nervous systems
where it normally represents approximately 4% of myelin lipids. (2, 12). Myelin
wraps around axons in a spiral fashion, creating a sheath that insulates neurons
from extracellular fluids and increases the electrical resistance across the cell
membrane, intensifying the transmission of electrical signals in the CNS (Figure
1.3) (13). Deficiency of ASA activity leads to the accumulation of non-degraded
sulfatide and this build-up can lead to levels representing up to 30% of the total
myelin membrane lipids and 40% of lipids found in metachromatic granules in
MLD patients. (6, 14) The increased levels of non-degraded sulfatide lead to
progressive demyelination in the CNS and PNS, resulting in the eventual death of
neuronal and glial cells as well as other secondary abnormalities such as the
storage and misallocation of unrelated lipids and inflammatory processes (6).
A cell culture model of sulfatide storage is not available and as such, the
processes leading to demyelination are not fully understood. Several
mechanisms have been proposed. Resorption of sulfatide from the innermost
layer of the myelin sheath is critical for its normal restructuring and is also
necessary to enable axons to increase their cross-sectional diameter. The ability
of myelin to undergo resorption may be compromised by sulfatide accumulations,
thereby affecting the plasma membranes of CNS and PNS cells, causing their
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Figure 1.2 Arylsulfatase A catalyzes the first step in the metabolism of sulfatide
(a). Hydrolysis by ASA breaks sulfatide down to galactocerebroside. This
substrate is then enzymatically degraded by galactocerebrosidase to ceramide
which is in turn broken down into fatty acid (b) (1). Any disruption along this path
can lead to accumulation of substrate.
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Myelin Sheath

Neuron

Figure 1.3 Sulfatide is found predominately as a vital component of myelin in the
CNS. Myelin sheaths wrap around axons in a spiral fashion, insulating the nerve
fibres and this myelination enables rapid transmission of nerve impulses. In the
CNS of patients with metachromatic leukodystrophy, axons become
demyelinated and instances of neuronal death occur.

breakdown (2, 6, 8). A study conducted by Ginsberg and Gershfeld (15),
indicated that myelin from MLD patients was incapable of forming normal lipid
bilayers due to a shift in the in the critical temperature of membrane bilayer
formation. This could result in a defective bilayer that can lead to the
degeneration of the myelin. It has also been suggested that
sulfogalactosylsphingosine (lysosulfatide), a lipid closely related to the highly
cytotoxic galactosylsphingosine, accumulates in MLD nervous tissue and that this
may reach toxic levels that destroy oligodendroctye and Schwann cell
functionality, leading to demyelination. (16, 17)
1.3 Treatm ent o f m etachrom atic leukodystrophy
To date, treatment of MLD is limited to palliative and supportive care.
Although some pharmacological agents may reduce physical symptoms such as
ataxia and spasticity, the administration of drugs to stabilize or activate mutant
ASA has been unsuccessful in halting the progression of disease (18, 19). The
major stumbling block encountered when designing drugs for the treatment of
diseases with major neurological impact is that large molecule drugs do not cross
the blood brain barrier. Options that have traditionally been available include the
administration of a drug via peripheral or invasive, trans-cranial injection. To date,
these have also met with unsatisfactory results (20).
The rationale behind many different treatments for MLD is based on cross
correction. Study designs take into account that during normal synthesis of
lysosomal enzymes, a small percentage (10-30%) of enzyme produced by a cell
is not directed to the lysosome but is secreted into the extra-cellular environment

slow turnover of resident tissue macrophages and microglia cells acting as
functioning sources of active enzyme cannot compete with the rapid progression
of the disease. (6, 18)
More recently, a phase l/ll clinical trial is currently underway under the
direction of Drs. A. Biffi and M. Sessa in the San Raffaele Telethon Institute for
Gene Therapy (HSR-TIGET) in Milan, Italy. This study is assessing the efficacy
of autologous hematopoietic stems cells that have been transduced with lentiviral
vector containing the normal human ASA gene. At the time of writing, one patient
had undergone treatment with favourable results but assessment of efficacy will
have to wait for long-term follow up (23).
1.4 Anim al model o f MLD
The lack of a naturally occurring animal model of MLD has historically held
back studies of both the pathogenesis and treatment of this disease (24). To
address this issue, Hess et al., generated a mouse model with ASA-deficiency.
These ASA (-/-) mice were developed using the targeted disruption of the ASA
gene in embryonic stem cells resulting in mice with a complete loss of ASA
activity. (3). Although ASA-deficient mice lack the widespread demyelination seen
in humans, the storage pattern of sulfatide resembles the pattern seen in MLD
patients (3, 24). Behavioural changes and gait disturbances are measurable by 6
months of age, correlating well with symptoms seen in human MLD patients (25).
These MLD models have enabled the investigation of various treatment
possibilities including gene therapy, direct injection of viral vectors into the brain,
and enzyme replacement therapy. (26)
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Several studies have used haematopoietic cells that have been
transduced with either retroviral or lentiviral vectors to over-express enzyme and
transplanted the modified cells into MLD mice. Allogenic bone marrow
transplantation has been used to populate the marrow of MLD mice with cells that
were retrovirally transduced to express functional human ASA to determine the
ability of enzyme to enter the brain tissue and act upon sulfatide stores (27).
Reduction of sulfatide in peripheral systems was noted but even though the
enzyme did translocate into the brain, no reduction of sulfatide was seen (28).
This is a different conclusion than that reached by Biffi et a i, who found that
following the transplant of lentiviral transduced haematopoietic stem cells
overexpressing ASA, MLD mice exhibited normalization of behavioural and gait
abnormalities. It was also noted that sulfatide storage was corrected in these
mice (29, 30). Caution is advised when interpreting these data. The lack of
demyelination in the MLD mouse means that the reversal of damages seen
cannot address the ability of these treatments to reverse demyelination seen in
human patients (26).
In 2005, Matzner et ai, treated MLD mice with weekly intravenous
injections of recombinant human ASA (rhASA). After four treatments, a reduction
in brain sulfatide levels was noted (31). Further treatments beyond the four-week
window, however, elicited a severe immunological response that caused high
mortality. In response, an MLD mouse was successfully generated that could
tolerate higher enzyme dosages for a longer period of time (32). These
immunotolerant mice were treated for 26 weeks with either a low dose or high
dose of enzyme and virtually none displayed apparent side effects. Those treated
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with a higher dose of enzyme exhibited reduction of lipid stored in the brain but
the storage reduction was similar to that seen in the previous study (31, 33).
Recombinant viral vector expressing recombinant enzyme has been
directly delivered into the brain by intracerebral injection to bypass the BBB,
enabling the enzyme to enter the brain where it is most needed. Injection of
vector has the potential to rapidly increase concentrations of ASA and have a
critical impact on the swift progression of the late-infantile form of MLD (26).
Results indicate that this form of gene transfer in the MLD mouse may reverse
some neurological damage In symptomatic mice as long as enzyme expression
persists.(4, 18, 34, 35). Injection of late-generation lentiviral vectors encoding
human ASA in 10-month old MLD mice resulted in sustained expression of
enzyme throughout a large portion of the brain and appeared to convey long-term
protection from developing neuropathology. In particular, lipid storage was
progressively reduced over time (34). Another group injected adeno-associated
virus serotype 5 (AAV5) vectors that encoded human ASA into the brains of both
pre-symptomatic and early symptomatic MLD mice (3 month old and 6 month old,
respectively). In the pre-symptomatic mice, delivery of the vector prevented
neuropathological abnormalities and neuromotor impairment. In the 3-month old
and the 6-month old mice, three months after injection of vector, reduced
sulfatide storage was noted and the level of sulfatide then remained stable. In
the 6-month old mice neuropathology was normalized but in contrast to the 3month old mice, treatment did not have an effect on neuromotor disability (4, 35,
36).

Although intracranial injections may hold promise for the treatment of
MLD, it is necessary for the enzyme to be distributed throughout the entire CNS.
This level of diffusion may be seen with as few as five injections across a mouse
brain but to cover the same relative area in a larger brain such as a human would
require many more injections (37). It is therefore important to scale studies in
order to appraise the efficiency of therapy in a larger brain. To this end, studies
by Colle et al., and Vite et al., indicate that multiple intracerebral injections of
enzyme-expressing vectors were well tolerated in larger animal models (38, 39).
It is important to note that intracranial injections are highly invasive and ideally
other forms of therapy, either alone or in conjunction with these more invasive
treatments, need to be explored.
1.5 Blood brain barrier and im plications in drug therapy
In 1885, Paul Ehrlich noted that vital dyes injected into the circulation
would stain all organs except the brain and spinal cord (40, 41). Soon thereafter,
scientists were further able to demonstrate that intravenous injection of acidic
dyes resulted in staining throughout the body with the exception of the brain and
spinal cord. Conversely they showed that injection of dye into cerebrospinal fluid
led to staining of the nervous tissues and resulted in pharmolocological effects
that were not seen with intravenous injections (42). These demonstrations were
the first to illustrate the inability of certain molecules to cross what was termed
the BBB.
Physiologically, the BBB consists of a layer of cerebrovascular endothelial
cells (CVEC) - pericytes, astrocyte foot processes, and some nerve endings
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(Figure 1.4). CVEC are highly specialized vascular endothelial cells fused
together with high resistance tight junctions. (43, 44). They also differ from other
endothelial cells in that they lack fenestrations and have very few pinocytotic
vesicles (45). These adaptations create the BBB that effectively prevents the free
flow of most molecules greater than 600 Da from passing from blood and
entering the brain tissue (46). Although this BBB effectively creates a privileged
site that has a critical protective function - this selectivity also results in an
inability of many therapeutic agents to reach their targets within the brain.
If the BBB can be breached, diffusion of a drug is of lesser concern.
Estimates suggest that a human brain contains approximately 100 million
capillaries that cover a surface area of ~12 m2 With approximately 40 pm of
space between human brain capillaries, there is room available for 2 neurons
between 2 capillaries. This suggests that virtually every neuron in the human
brain is perfused by its own capillary. Therefore, the short intercapillary distance
can enable diffusion of the drug throughout brain tissue (37, 47) resulting in a
uniform and immediate increase of drug concentration through the brain. The
problem then is not necessarily the CNS drug itself but rather the targeting of the
drug into the CNS (20).
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Brain Parenchyma
on Abluminal Side of the BBB

Figure 1.4 The blood brain barrier acts to prevent the passage of solutes
between the blood and brain parenchyma. It is comprised of cerebrovascular
endothelial cells (CVEC), pericytes, astrocytes foot processes, and periodically,
a nerve ending. CVEC are a specialized vascular endothelial cell lacking
fenestrations and produce very few pinocytotic vesicles. CVEC are fused
together with high resistance tight junctions. These adaptations prevent most
molecules greater than 600 Da from entering the brain tissue (46).

15

1.6 Crossing the blood brain barrier

The passage of molecules into or out of the brain interstitial fluid is subject
to highly regulated processes due to the high-resistance tight junctions of the
blood-brain barrier. There are three methods by which solutes typically cross the
BBB: carrier-mediated transport (CMT); active-efflux transport (AET); and
receptor-mediated transport (RMT) (44). Carrier-mediated transport systems
enable the passage of essential small polar molecules such as water-soluble
vitamins, amino acids and glucose from either the blood-to-brain direction or the
brain-to-blood direction (44, 48, 49). Active-efflux transport (AET) enables the
efflux of low molecular mass products from the brain into the blood (44). The
passage of most non-lipid solutes or those larger than 600 Da occurs by
receptor-mediated transport (RMT) whereby receptors such as the insulin
receptor, low-density lipoprotein receptor (LDLR), and transferrin receptor (TfR)
on the cerebrovascular capillary wall recognize and bind their respective ligands
such as insulin, cholesterol, and iron. These receptor-ligand complexes are
endocytosed into the cerebrovascular endothelial cell. Some of the internalized
solutes are then transported across the capillary wall where they can be delivered
into the brain parenchyma (Figure 1.5). (50, 51).
1.7 M olecular Trojan horses
For several years, various groups have explored the possibility of using
receptor-mediated transport to deliver various agents into the brain (37, 52-56). A
developing interest in the protein or peptide ligands that bind receptors on the
blood brain barrier has led to their use as molecular “Trojan horses”. These
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(Blood)
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Cerebrovascular
Endothelial Cell

Figure 1.5 Receptor-mediated transcytosis of protein across the blood brain
barrier. Circulating protein is recognized as ligand by specific cell-surface
receptors (a) and endocytosed by cerebrovascular endothelial cells (CVEC) (b).
This protein can be transported across the blood-brain barrier and delivered to
the abluminal side of the CVEC for entry into the brain parenchyma (c). Adapted
from Pardridge, 1999.
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Trojan horses are fused to various therapeutic agents to generate recombinant
fusion protein that bind endogenous receptors on the blood brain barrier, shuttling
the fused product from the bloodstream across the BBB and into the brain where
they can deliver the therapeutic payload into the brain tissue. In order to be
effective, Trojan horses must target an endocytotic BBB system; maintain high
affinity for the receptor as a Trojan horse-drug fusion product; there must be high
uptake of the fusion protein; and following uptake, the system must exhibit a
therapeutic effect in the CNS (20).
A variety of different proteins or peptides have been used as Trojan horses
including monoclonal antibodies to the human insulin receptor (HIR) (52, 53, 5759); monoclonal antibodies to mouse transferrin receptor (MAbTfR) (56); and
apolipoproteins that bind low-density lipoproteins receptors(LDLR)(37).
Molecular Trojan Horses offer a new approach for targeting therapy across the
BBB into the brain to treat diseases with neurodegenerative effects.
1.8 Thesis introduction
In principle ASA delivery into the nervous system would correct the
enzyme deficiency in MLD but the blood brain barrier (BBB) prevents the enzyme
from entry. With the current lack of successful treatment for metachromatic
leukodystrophy, there is a need to push forward with new therapeutic options and
develop biopharmaceutical drugs that could help ameliorate symptoms of this
devastating disease. The recent use of Trojan horse technology offers such an
approach to treating this neurodegenerative disease.
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The LDL receptor (LDLR) can enable protein transport across the BBB via
receptor-mediated transcytosis. LDLR is expressed on the apical (blood) side of
the BBB and transcytoses lipids bound to apolipoproteins to the basolateral
(brain) side (84).
Normally, apolipoprotein E combines with circulating lipids and targets
them for catabolism. The ApoE-lipid complex is endocytosed by cells after
binding to cell-surface LDL receptors and these complexes are typically targeted
to lysosomes and with the receptor released to be recycled to the cell surface
(60). At the BBB, however, ApoE complexes bound to the LDLR are transcytosed
to the abluminal face of the BBB and exported into the brain parenchyma (60,
61). This transfer of ApoE is critical for the delivery of cholesterol in both the
development and repair of axons (12).
In 2007, Spencer and Verma fused apolipoprotein B to
glucocerebrosidase. The apolipoprotein portion of the fusion protein was able to
bind LDLR, crossed the BBB and successfully delivered active
glucocerebrosidase into the brain of mice. Following the delivery of enzyme
across the BBB with Trojan horse technology, active glucocerebrosidase was
determined to have located to the lysosomes of neurons and astrocytes of the
CNS (37).
In this thesis, I hypothesize that the LDLR-binding site of Apolipoprotein E
can be fused to full-length ASA. This fusion protein will bind to the low density
lipoprotein receptors expressed on the vascular side of endothelial cells of the
blood brain barrier leading to the transport of arylsulfatase A to endothelial cell
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lysosomes, retaining enzyme activity. Furthermore, ASA will pass through the
blood brain barrier by exocytosis and enter into the CNS.
Following the Spencer and Verma model, the purpose of this research
project was to construct a fusion protein containing V5-epitope-tagged
arylsulfatase A fused to the LDLR binding region of ApoE. The retention of
bifunctionality of this fusion protein was assessed for both the ability of the ApoE
fragment to facilitate protein endocytosis as well as the ability of the fused
arylsulfatase A to exhibit enzymatic activity. Constructs were built with the ApoE
peptide at the C-terminus of ASA-V5 and they were assessed for in vitro
enzymatic activity and kinetic properties. A second fusion protein was
constructed using the ApoE peptide at the C-terminus eGFP to enable visual
confirmation of the ability of the ApoE fragment to be taken up by cell cultures. A
third fusion protein, concurrently developed in the laboratory, was similarly
constructed with the full-length murine transferrin protein at the N-terminus of V5epitope-tagged ASA. These fusion proteins were expressed in Chinese Hamster
Ovary (CHO) cells transduced with lentiviral expression vectors using the
Invitrogen MultiSite Gateway® Pro kit. Expressed proteins were isolated and
delivery of active enzymes through an in vitro blood-brain barrier developed by
the Cepinskas lab at the Lawson Health Research Institute was assessed.
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Chapter 2 - Materials and Methods
Generating fusion proteins
To generate the desired fusion products, MultiSite Gateway® Pro Kit
(Invitrogen) was used. This technology ensured that both DNA elements of the
fusion proteins were inserted into destination vectors in the correct order and
orientation. To accomplish this, forward and reverse primers for each construct
were designed that incorporate specific att-sites flanking the PCR products
(Table I). The att-flanked PCR products underwent a recombination event to
insert the sequence of interest into donor vectors to generate entry clones. Entry
clones were then used in a second recombination event with destination vectors
to generate expression clones expressing the fusion protein (Figure 2.1).
2.1 Polymerase chain reaction (PCR)
Amino acids, RARLSTHLRKMRKRLMR, encompassing the LDLR-binding
region of murine ApoE (87, 88, UniProtKB/Swiss-Prot P08226.2) were PCRamplified from genomic DNA of C57B16 mice (supplied by this laboratory) using
forward and reverse primers C-ApoE-F and C-ApoE-R (Table I) to generate DNA
element C-ApoE.
The full-length eGFP sequence, including the Kozak consensus sequence
cgccacc upstream of the start codon, was PCR-amplified from peGFP-N1
(GenBank Accession #1155762, Figure 2.2) using primers N-eGFP-F and NeGFP-R (Table I) to generate DNA element N-eGFP.
Full-length human arylsulfatase A with a C-terminus V5 epitope tag was
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(a)

PCR
Product
Donor
Vector

(b)

(c )

Figure 2.1 Target DNA is amplified in PCR reactions with primers containing
specific att sites to generate att-flanked amplicons (a). Two PCR products
undergo separate recombination events with two donor vectors to generate entry
clones (b). These two entry clones undergo a second recombination event
together with a destination vector to create an expression clone containing both
original DNA elements in correct orientation (c).

Entry
Clone

Primer
Set

Sequence {5! - 3’}

N-ASA

N -A S A -F

G G G G A C A A G T T T G T A C A A A A A A G C A G G C T G G A T G G G G G C A C C G C G G T C C C T C CT C

N -A S A - R

G G G G AC A A C T T T T G T A T A C A A A G T T G TC G T A G A A T C G A G A C C G A G G AG

N -e G F P -F

G G G G AC A A G T T T G T A C A A A A A A G C A G G C T GG CG C C AC C AT G G T G A G C A A G G G CG A G G A G C T G

N -e G F P -R

G G G G A C A A C T T T T G T A T A .C A A A G T T G T C T T G T A C A G C T C G T C C A T G C C G A G A G T

C -A p o E -F

G G G G A C A A C T T T G T A T A C A A A A G T T G A A A T G C G G G C G C G G C T C T CC A C A C A C

C -A p o E -R

GGG GAC C AC TTT G TA C A A G A A A G C TG G G TA C TA C C G CAT C AAG C G C TT G CG CAT

N-eGFP

C-ApoE

Table l To generate entry clones, forward and reverse primers were designed to incorporate specific att sites into
PCR products for insertion in specific pDONR™ entry vectors using Invitrogen’s MultiSite Gateway® Pro kit. The
nucleotide sequences that constitute the att sites are underlined.
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Figure 2.2 Full length eGFP was PCR-amplified from the plasmid, peGFP-N1
(GenBank Accession #1155762) with primers containing specific flanking aft-sites.
Amplicons were used in downstream events to generate fusion proteins
designated GFP-ApoE. Illustration from Clontech Laboratories
(http://www.clontech.com).
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PCR-amplified from pLenti6.3-v5GW-asaV5 (supplied by this laboratory, Figure
2.3) using primers N-ASA-F and N-ASA-R as listed in Table I to generate DNA
elements N-ASA.
PCR was performed in an Eppendorf® Mastercyclergradient thermocycler
using Pfx50™ DNA polymerase and buffer reagents supplied by Invitrogen with
the following thermal cycling conditions:

C-ApoE

Initial
Denaturation at
94°C
3 min

N-GFP

2 min

N-ASA

2 min

PCR product

Anneal at
68°C/Extension at 94°C
45 sec/15 sec
(30 cycles)
2 min 10 sec/15 sec (25
cycles)
2 min 10 sec/15 sec
(30 cycles)

Final Extension at
68°C
5 min
5 min
5 min

Samples of PCR product were loaded on 1.2% agarose gel and
electrophoresed for visualization (FlashGel® system, Lonza USA).
Each PCR product was subsequently purified to remove att primers and
primer-dimers. Both N-eGFP and N-ASA PCR products were purified using
polyethylene glycol (PEG) purification. Briefly, 75 pi 1XTE buffer (Tris-EDTA, pH
8.0) was added to 25 pi of amplification reaction mixture containing att-flanked
PCR product followed by the addition of 50 pi 30% PEG 8000/30 mM MgCI2
(supplied with MultiSite Gateway® Pro, Invitrogen). The mixtures were mixed
thoroughly and centrifuged at 10,000 x g for 15 min at room temperature. The
supernatant was removed and the remaining pellet was dissolved in 25 pi 1X TE
buffer and stored at -20°C for downstream applications.
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Figure 2.3 Full length ASA with a C-terminus V5 epitope tag was PCR-amplified
with primers containing specific flanking aft-sites from the plasmid, pLenti6.3v5GW-asaV5. Amplicons were used in downstream events to generate fusion
proteins designated ASAApoE. Control expression clones were also generated
using this plasmid.

C-ApoE PCR products were gel purified from 4% agarose using the PureLink™
Quick Gel Extraction kit (Invitrogen) according to the manufacturer’s
instructions. Briefly, the area of the gel containing C-ApoE was excised and
dissolved in 2 volumes of gel solubilization buffer in a 50°C water bath for 30 min.
Following the addition of isopropanol, all product was transferred onto an
extraction column. Samples were centrifuged and washed with wash buffer
containing ethanol. The samples were incubated for 1 min with elution buffer and
purified PCR products were pelleted by centrifugation and stored at -20°C for
downstream applications.
The quality and quantity of all purified DNA products were measured by
spectrophotometry (NanoDrop™ 1000 Spectrophotometer, Thermo Scientific)
and were visualized using either 1.2% or 2.2% agarose gel electrophoresed for 57 min at 275V (FlashGel® system, Lonza USA).
2. 2 Creating entry clones with pDONR™ vectors
Entry clones were generated using a BP recombination event that inserted
purified PCR amplicons into specific pDONR™ vectors to generate entry clones
that would be used in downstream second recombination events (Figure 2.1).
2.2.1 BP reaction
PCR elements N-ASAV5 and N-eGFP were inserted into pDONR 221 P1P5r and element C-ApoE was inserted into pDONR 221 P5-P2 (Figure 2.4) as a
result of a BP recombination event. Gateway BP Clonase™, an enzyme mixture
containing Integration Host Factor (IHF) and Integrase proteins catalyzed the
insertion of the PCR product into donor vectors. Briefly, 15-150 ng of each att-

Figure 2.4 aff-flanked PCR amplicons were used in BP recombination events along with pDONR entry vectors from
Invitrogen’s MultiSite Gateway® Pro kit to generate entry dones. DNA elements containing either the full-length
hASAV5 or full-length eGFPwere inserted into pDONR™ 221 P1-P5r. The LDLR-binding region of murine ApoE was
inserted into pDONR™ 221 P5-P2. Figure adapted from Invitrogen.

flanked PCR product was combined with 100 ng/pl of the appropriate pDONR
vector, 2 pi Gateway BP Clonase II, and 1X TE buffer (pH 8.0) for a total volume
of 10 pi. Samples subjected to the same conditions and reagents with the
exception of BP Clonase II were included as negative controls. All mixtures were
incubated for 4 hours at 25°C. To stop reactions, 1 pi Proteinase K (2 pg/pl) was
added and incubated for 10 min at 37°C.
2.2.2 Transformation reaction of

E . c o li

with entry clones

To transform competent E. coli cells, 2 pi of each BP reaction mixture
generated was added to a vial of One Shot® M achl™ T1R Competent E.coli.
Transformation mixtures were incubated on ice for 30 min followed by a 30 sec.
heat-shock treatment at 42°C and immediately placed on ice for 2 min. After the
addition of 250 pi of room temperature S.O.C. medium (2% tryptone, 0.5% yeast
extract, 10 mM NaCI, 2.5 mM KCI, 10 mM MgC^, 10 mM MgS04, 20 mM
glucose), vials were shaken at 225 rpm for 1 hour at 37°C. Each transformation
mixture was spread on pre-warmed selective LB agar plates (37.0 g/L Luria
Bertani agar with 50 pg/ml kanamycin) and incubated overnight at 37°C.
2.2.3 Entry clone isolation
E. coli carrying entry clone plasmids were positively selected based on
their ability to grow colonies in the presence of kanamycin. Discrete colonies
were selected and incubated overnight at 37°C in LB medium containing 50 pg/ml
kanamycin with shaking (225 rpm). Plasmid DNA (pDNA) was isolated by miniprep isolation methods based on modified alkaline lysis methods (62) using either

the ChargeSwitch® NoSpin Plasmid Kit (Invitrogen) or the QIAprep® Spin
Miniprep Kit (Qiagen) according to manufacturers’ instructions.
The ChargeSwitch NoSpin Plasmid Kit uses magnetic beads with a
switchable surface charge to isolate plasmid DNA. Briefly, transformed bacteria
were bound to magnetic beads and pelleted. Supernatant was removed and the
bead-bound cells were resuspended in buffer containing RNase A. Lysis buffer
was added to the suspension and the mixture was incubated for up to 5 min.
Following the addition of precipitation buffer, cellular debris became bound to the
magnetic beads and was pelleted. Supernatant, now containing pDNA, was
transferred and bound to fresh magnetic beads in new tubes. pDNA was washed
twice followed by elution of plasmid when the pH was raised using the supplied
elution buffer.
To begin isolating pDNA using the QIAprep® protocol, cell cultures were
harvested by centrifugation. Bacteria carrying plasmids were lysed in lysis buffer
with RNase A. The lysate was neutralized and adjusted to high-salt followed by
centrifugation to precipitate debris, leaving DNA in suspension. The suspension
was transferred to columns for adsorption of DNA and washed twice. Elution
buffer was added, and the solution was centrifuged, eluting entry clone plasmids
into Tris buffer.
Quality and quantity of isolated plasmid DNA was analyzed by
spectrophotometry (NanoDrop™ 1000 Spectrophotometer). Candidate samples
were sent for sequencing at the DNA Sequencing Facility at Robarts Research
Institute using M13F (-20) and M13R sequencing primers (Table II).
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Transformed colonies containing complete and accurate sequences were
incubated overnight at 37°C with shaking in LB medium with 50 pg/ml kanamycin.
Plasmid DNA (pDNA) was isolated using midi-prep isolation using the PureLink™
HiPure Midiprep kit (Invitrogen) following manufacturer’s instructions. This
isolation method uses anion-exchange chromatography whereby bacteria is
harvested and resuspended in resuspension buffer with RNase A. Cells were
lysed in lysis buffer, precipitation buffer was added and debris was pelleted using
centrifugation. Supernatant containing plasmid DNA was passed through anion
exchange columns, binding DNA to the column. The column was washed to
remove impurities and the DNA was eluted with supplied elution buffer. The
eluted DNA was desalted and concentrated using an alcohol precipitation and
subsequently resuspended in Tris buffer.
Quality and quantity of pDNA was analyzed by spectrophotometry
(NanoDrop™ 1000 Spectrophotometer). Entry clones were designated:
pNASAV5, pCApoE, and pNeGFP.
2.3 Creating expression clones using pcDNA 6.2/V5-DEST vectors
To generate expression vectors encoding the desired fusion proteins, two
entry clones and the pcDNA 6.2A/5-DEST Gateway® vector (Figure 2.5) were
used in an LR recombination event. This reaction simultaneously transferred
both DNA fragments into the destination vector. Reaction mixtures were
transformed into competent E. coli and expression clones were selected for.
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Primer
M13F (-20)
M13R
P1F
P2F
P3F
P4F
T7 Promoter
V5R
CMV

Sequence (5’ - 3’)
5-GTAAAACGACGGCCAG-3'
5-CAGGAAACAGCTAT GAC-3'
5'-AGTGCGCGAGCAAAATTTAAG-3'
5'-GTT CGGAT GGGCATGTACCCT-3'
5-CTCCCTGATGGAGCTGGATGC-3'
5'-ACTGCT CATGAGCCCCCGCT G-3'
5'-TAATACGACT CACTATAGGG-3'
5-ACCGAGGAGAGGGTTAGGGAT-3'
5-CGCAAATGGGCGGTAGGCGTG-3'

Table II Entry and expression clones were sent to the DNA Sequencing Facility
at the Robarts Research Institute for sequencing. Entry clones pN-ASAV5, pNeGFP, and C-ApoE were sequenced using M13F (-20) and M13R primers.
Expression clones used the following sequencing primers: pASAV5ApoE
expression clones used P1F, P2F, P3F, P4F; pGFPApoE expression clones used
T7 promoter and V5R; pLvASAApoE used CMV, P2F, P3F, P4F; and
pLvGFPApoE used CMV and V5R.
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2.3.1 LR reaction
Each entry clone was used in a LR recombination reaction (Figure 2.1) to
insert DNA elements into destination vectors to generate expression clones.
Entry clones were paired up to include both N-terminus targeted DNA elements
and C-terminus targeted DNA elements: pNASAV5 and pCApoE; pNeGFP and
pCApoE. These reactions required the use of Gateway® LR Clonase® Plus, an
enzyme mixture containing Integrase, IIHF, and Excisionase enzymes to catalyze
recombination between entry clones and pcDNA 6.2A/5-DEST (Figure 2.5).
Briefly, 10 fmoles of each appropriate entry clone was combined with 20 fmoles
of destination vector, 1X TE Buffer, and 7pl of LR Clonase™ Plus enzyme.
Mixtures were vortexed briefly and incubated at room temperature for 16 hr. To
stop the reaction, 1 pi of Proteinase K solution (2 pg/pl) was added and tubes
were incubated for 10 min at 37°C. Negative controls were subjected to the same
conditions and reagents with the exception of LR Clonase™ Plus which was
omitted.
2.3.2 Transformation reaction o f E. co/i with pcDNA 6.2/V5-DEST
To transform competent E. coli cells, 2 pi of each LR reaction mixture
generated was added to a vial of One Shot® Machl ™ T1R Competent E.coli
(Invitrogen). To generate control expression clones encoding ASAV5
(pLvASAV5), a vial of One Shot® Machl ™ Competent E.coli was transformed
with 100 ng of pLenti6.3-v5GW-asaV5 (Figure 2.3, supplied by this laboratory).
The same protocol for the transformation reaction was used in section 2.2.2 with
the exception of the selective agar: each transformation mixture was spread on
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Figure 2.5 Entry clone pCApoE and either pNASAV5 or pNeGFP were used in
LR recombination events along with the pcDNA™A/5-DEST expression vector
from Invitrogen to generate expression plasmids pASAApoE and pGFPApoE.
Figure adapted from Invitrogen.

34

pre-warmed selective LB agar plates (37.0 g/L LB agar with 100 pg/ml
carbenicillin). Expression clones for eGFP expression (pLvGFP) to be used as
controls were generated by growing Stbl3 E.coli transformed with pLenti6.3V5GW-GFP (Figure 2.6, supplied by this laboratory) on LB agar with 100 pg/ml
carbenicillin overnight at 37°C.
2.3.3 Expression clone isolation
E. coli carrying expression clone plasmids were positively selected
based on their ability to grow colonies in the presence of carbenicillin. Discrete
colonies were selected and incubated overnight at 37°C in LB medium containing
100 pg/ml carbenicillin with shaking (225 rpm). pDNA was isolated by mini-prep
isolation methods based using QIAprep® Spin Miniprep Kit (Qiagen) according to
manufacturer’s instructions (see 2.2.3 above). Quality was analyzed by
spectrophotometry (NanoDrop™ 1000 Spectrophotometer). Candidate samples
were sent for sequencing at the DNA Sequencing Facility at Robarts Research
Institute and expression clones were designated pASAApoE, and pGFPApoE. A
nested set of sequencing primers (P1F, P2F, P3F, P4F) were used to sequence
pASAApoE. To sequence pGFPApoE, T7 promoter primer and V5 reverse
primer were used (Table II). Transformed colonies containing complete and
accurate sequences were grown and pDNA purified by midi-prep isolation
methods listed previously. Quality and quantity of pDNA was analyzed by
spectrophotometry (NanoDrop™ 1000 Spectrophotometer).
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Figure 2.6 Full length eGFP was PCR-amplified from the plasmid, pLenti6.3V5GW-GFP with primers containing specific flanking aff-sites. Amplicons were
used in downstream events to generate fusion proteins designated GFPApoE.
This plasmid was also used to transform competent E.coli and used to generate
control expression clones
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2.4 Transfection of CHO cell lines with pASAApoE and pGFPApoE
2.4.1 Cell culture
Chinese hamster ovary cells (CHO DG44) that were used for
experiments were dihydrofolate reductase (DHFR)-deficient cells adapted to be
an adherent cell line by this laboratory. Cells were maintained in complete CHO
medium composed of HyClone DMEM/F-12 (Dulbecco’s Modified Eagle
Medium/Nutrient Mixture F-12, Thermo Scientific), 10% fetal bovine serum (FBS,
Gibco by Invitrogen), and 1X antibiotic-antimycotic (Gibco) at 37°C in 5% C 0 2.
Cells were passaged when confluent using TrypLE™ Express (Gibco) to
dissociate CHO cells from cultureware and transferred into T-75 cm2 flasks (BD
Biosciences).
2.4.2 Plasmid transfection
To increase likelihood of expression in transfected cells, plasmids were
linearized using restriction endonucleases to cleave plasmids in a location
outside of any critical elements and outside of the recombinant gene sequence.
Plasmids carrying the fusion constructs (pASAApoE, pGFPApoE) were linearized
using Sapl (New England BioLabs) and plasmids carrying controls (pLvASAV5,
pLvGFP) were linearized using Sspl (New England BioLabs). Briefly, 2 pg of
plasmid were combined with 5 pi 10x buffer (supplied) and dH20 to a final volume
of 50 pi. Restriction enzyme was added (3 pi Sapl or 1.5 pi Sspl) and mixtures
were incubated at 37°C for 3 hr and heat-inactivated at 65°C for 20 min. Aliquots
were electrophoresed on 0.8% agarose gel and visualized with ethidium bromide
to assess linearization. Images of gels were captured using BioRad Gel Doc UV-
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Transilluminator Imaging System and annotated and analyzed using Quantity
One® 4.6.1 quantitation software.
Plasmids were ethanol precipitated. Briefly, 1/10 of a volume of 3 M
sodium acetate buffer (pH 5.2) and 2-/4 volumes of ice cold 100% ethanol were
added to samples and stored at -20°C for a minimum of 1 hr. pDNA was
pelleted by centrifugation at 10,000 x g for 15 min at 4°C and the supernatant
was discarded. The pDNA pellet was washed with cold 70% ethanol and
centrifuged for 10,000 x g for 5 min at 4°C. The pelleted plasmid was air dried for
10 min and resuspended in Tris-EDTA buffer. Quality and quantity of linearized
plasmids were analyzed by spectrophotometry (NanoDrop™ 1000
Spectrophotometer).
Transfection of plasmid DNA into CHO cells was performed in duplicate
using Lipofectamine™ LTX and PLUS™ reagents (Invitrogen). One day before
transfection, CHO cells were seeded with complete CHO medium into 24-well
plates and incubated at 37°C with 5% C 0 2. When cells reached 70-80%
confluence, media was removed and replaced with 0.5 ml fresh DMEM/F-12
medium containing 10% FBS (Gibco). For each transfection reaction, 0.5 pg of
plasmid was diluted into 100 pi Opti-MEM® I reduced-serum medium (Invitrogen)
and 0.5 pi of PLUS™ reagent was added. These mixtures were incubated for 5
min at room temperature and 1.7 pi of Lipofectamine™ LTX was added. The
DNA-lipid mixture was incubated for 30 min at room temperature and DNA-lipid
complexes were added. Mock transfections were set up using naive CHO cells
without the addition of lipofectamine as well as naive CHO cells incubated with
lipofectamine but without pDNA. Plates were then incubated at 37°C in 5% C 0 2
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for 4-6 hr. Any unattached complexes were removed, replaced with DMEM/F-12
medium containing 10% FBS (Gibco), and returned for incubation. After 48 hr,
the medium was replaced with CHO complete medium containing 3 pg/ml
blasticidin to select for stable transfectants. Medium was replaced with fresh
blasticidin-containing medium every 48-72 hr for 11 days until stable
transfectants were firmly established.
2.5 Detecting recombinant fusion proteins expressed by stable
transfectants
2.5.1 Detection of eGFP expression
To detect eGFP expression, live CHO cells transfected with pGFPApoE
and pLvGFP were visualized using fluorescence microscopy. All images were
obtained using a Leica DMIRB fluorescence microscope equipped with a
Qlmaging Retiga 1300 camera and processed with Improvision Openlab
software.
Fluorescence in collected cell lysate and cell media (see section 2.5.2)
was measured with excitation/emission wavelengths of 471/508 nm using a
multimode microplate reader (Varioskan™, Thermo Electron Corp.) controlled by
Skanlt® software, version 2.2.
2.5.2 Collection o f cell lysate and media
Each stable transfected cell line (transfected with pASAApoE,
pGFPApoE,pLvGFP, and pLvASAV5) and naive CHO cells were grown to
confluence and harvested. Briefly, cells were washed four times with chilled
DMEM/F-12. Cells were gently scraped, suspended in cold DMEM/F-12 medium,
and then pelleted by centrifugation at 1,000 x g for 5 min at 4°C. Cells were

resuspended in 3 ml chilled 20mM Tris (pH 8.0) and lysed by sonication. Lysate
was cleared of cellular debris by centrifugation at 20,000 x g for 15 min at 4°C
and supernatant was carefully removed.
Conditioned medium was collected from CHO cells expressing ASAV5
and ASAApoE every 48-72 hr, centrifuged at 12,000 x g for 5 min at 4°C to pellet
cellular debris, and filter-sterilized through 0.2 pm sterile syringe filters (VWR).
2.5.3 Assessing enzyme activity
The cell homogenate and/or supernatant from CHO cells transfected
with pApoEASA, pASAApoE, and pLvASAV5 were analyzed for arylsulfatase A
activity using p-nitrocatechol sulfate (pNCS) as substrate according to Gordon
and Rip (63). Samples of media or cell homogenate (50 pi) were incubated in
standard 96-well plates with 50 pi p-NCS solution in sodium acetate buffer (10
mM, pH 5.0) at 4°C. Blanks containing 50 pi sample only were incubated under
the same conditions. After 48-72 hours, all assays were terminated with the
addition of 150 pi of 1M NaOH and 50 pi of pNCS solution was added to blanks.
All samples were analyzed spectrophotometrically at 516 nm using a multimode
microplate reader (Varioskan™, Thermo Electron Corp.) controlled by Skanlt®
software, version 2.2 and absorbance values converted to nanomoles (nmol)
activity of ASA. Numbers were standardized by dividing the nmol of pNCS
cleaved by the number of hours the assays were run (nmol/hr).
2.6 Generating lentiviral expression plasmid
To increase the stability and expression levels of fusion proteins,
lentiviral expression plasmids were generated using entry clones pNASAV5,
pCApoE, and pNeGFP previously produced (see Chapter 2.2). Two entry clones
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and the pLenti6.3/V5-DEST expression vector (Figure 2.7) were used in an LR
recombination event. Following recombination, mixtures were transformed into
competent E.coli and expression clones were selected based on growth in the
presence of antibiotic.
2.6.1 LR reaction
Following the LR reaction method detailed in Chapter 2.3.1,
pLenti6.3/V5-DEST vectors were used in conjunction with entry clones listed
above to generate lentiviral-based expression clones (pLenti). pNASAV5 and
pCApoE were paired together to generate expression clone, pLvASAApoE.
pNeGFP and pCApoE were used to generate expression clone pLvGFPApoE.
2.6.2 Transformation reaction of

E. c o li

with pLenti

To transform competent E. coli cells, 3 pi of each LR reaction mixture
was added to a vial of One ShotR Stbl3™ Chemically Competent E. coli
(Invitrogen). Transformation mixtures were incubated on ice for 30 min followed
by a 30 sec. heat-shock treatment at 42°C and immediately placed on ice for 2
min. Mixtures were transferred to conical tubes containing 1 ml of pre-warmed
S.O.C. medium and were shaken at 225 rpm for 1 hour at 37°C. Each
transformation mixture was spread on pre-warmed selective LB agar plates (37.0
g/L Luria Bertani agar with 100 pg/ml carbenicillin) and incubated overnight at
37°C.
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Figure 2.7 Entry clone pCApoE and either pNASAV5 or pNeGFP were used in
LR recombination events along with the pLenti6.3A/5-DEST expression vector
from Invitrogen to generate expression plasmids pLvASAApoE and
pLvGFPApoE. Figure adapted from Invitrogen.
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2.6.3 pLenti expression clone isolation
E. coli carrying lentiviral-based expression clone plasmids were
positively selected based on their ability to grow colonies in the presence of
carbenicillin. Discrete colonies were selected and incubated overnight at 37°C
with shaking (225 rpm) in LB medium containing 100 pg/ml carbenicillin. pLenti
DNA was isolated by mini-prep isolation methods using the QuickLyse Miniprep
Kit (Qiagen) following the manufacturer’s instructions. Briefly, 1.5 ml transformed
E. coli cells were pelleted by centrifugation. The medium was decanted and lysis
solution was added. Contents were vortexed for 30 sec and allowed to incubate
for 3 min at room temperature. The lysate was transferred to a QuikLyse spin
column and centrifuged. The contents of the spin column were washed,
centrifuged, and the flow through was discarded. Following another round of
centrifugation to dry the column, the column was placed into a clean collection
tube and elution buffer was added. pLenti DNA was eluted by centrifugation and
stored at -20°C. Quality was analyzed by spectrophotometry (NanoDrop™ 1000
Spectrophotometer). Samples were sequenced at the DNA Sequencing Facility
at Robarts Research Institute using the CMV forward primer and P2F, P3F, and
P4F for sequencing pLvASAApoE expression clones. The CMV forward primer
and V5R reverse primer were used to sequence pLvGFPApoE clones (Table II).
2.7 Restriction enzyme analysis of pLenti
pLenti DNA was analyzed by restriction digestion to confirm
rearrangement in the LTR regions of the plasmid had not occurred using a
combination of endonucleases AflU and Xho\. All reagents were supplied by New
England BioLabs. Briefly, 1 pg of each expression clone was diluted to 17 pi in
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deionized water and mixed gently with 2 |j| of 10X Buffer and 0.2 pi bovine serum
albumin (BSA). Aflll and Xhol (10 U each) were added and mixtures were
incubated at 37°C for 3hr. Enzyme activity was heat-inactivated for 20 min at
65°C. Aliquots were electrophoresed on 0.8% agarose gel and visualized with
ethidium bromide to assess fragment sizes. Images of gels were captured using
BioRad Gel Doc UV-Transilluminator Imaging System and annotated and
analyzed using Quantity One® 4.6.1 quantitation software.
Transformed colonies containing complete and accurate sequences
were grown and pLenti was isolated by midi-prep isolation methods based on
modified alkaline lysis methods (62) using a QIAfilter Plasmid Purification Kit
(Qiagen) following manufacturer’s instructions. Briefly, transformed E.coli cells
were pelleted by centrifugation. The pellet was resuspended in the supplied
resuspension buffer and lysis buffer was added, and the mixture incubated for 5
min at room temperature. Precipitation buffer was added and contents were
immediately transferred to the barrel of a Qiafilter cartridge followed by incubation
at room temperature for 10 min to allow precipitates to float to the top on the
cartridge. The lysate was then filtered into an equilibrated Qiagen tip containing
an anion-exchange resin, binding pLenti DNA. The Qiagen tip was washed twice
with supplied buffer and pLenti DNA was eluted using supplied elution buffer.
The pLenti DNA was precipitated with room-temperature isopropanol and
pelleted by centrifugation. The supernatant was discarded and the pellet was
washed with 70% ethanol, followed by centrifugation. The pellet was air dried
and pLenti DNA was redissolved in a 100 pi TE buffer (pH 8.0). Quality and

quantity of pDNA was analyzed by spectrophotometry (NanoDrop™ 1000
Spectrophotometer).
2.8 Lentivirus production
ViraPower™ Packaging Mix (Invitrogen) and the pLenti expression
clones, LvASAApoE and LvGFPApoE, were co-transfected into a 293FT
producer line to produce two different replication incompetent lentiviral stocks
following the manufacturer’s instructions. The titer of each virus was measured
and lentiviral stocks were used to transduce CHO-DG44 cell lines.
2.8.1 Propagating 293FT producer ceil lines
The initial 293FT cell lines were provided by this laboratory and
maintained in 293FT complete DMEM media (high glucose Dulbecco’s Modified
Eagle Medium, 10% FBS, 0.1 mM MEM Non-Essential Amino Acids, 2 mM Lglutamine, and 1X Anti-Anti) supplemented with 500 pg/ml Geneticin. Cells were
incubated at 37°C in 5% CO2 and passaged when confluent. All cell culture
reagents were supplied by Gibco.
2.8.2 Co-transfection o f 293FT cells with ViraPower™ and pLenti
expression clones
One day prior to co-transfection, 293FT cells were seeded in 293FT
complete media without antibiotic in T-75 cm2 flasks (BD Biosciences) at a
density to ensure that cells would be ~90-95% confluent for transfection. Cells
were incubated overnight at 37°C in 5% C 0 2.
On the day of transfections, 293FT culture medium was discarded and
replaced with 5 ml of 293FT complete medium supplemented with 1mM sodium
pyruvate (Gibco) without antibiotic. For each transfection reaction, 9 pg of pLenti

and 3 pg of ViraPower™ packaging mix were diluted into 1.5 ml OptiMEM I
Medium. Thirty-six pi of Lipofectamine™ 2000 was diluted in 1.5 ml of OptiMEM I
Medium and incubated for 5 min at room temperature. Following incubation,
diluted lipofectamine was added to pLenti mixture, mixed gently, and incubated
for 20 min at room temperature to allow DNA-lipofectamine complexes to form.
Complexes were added drop wise to 293FT cells in flasks, mixed gently, and
incubated overnight at 37°C in 5% C 0 2. The following day, 293FT medium
containing DNA-lipofectamine complexes was replaced with 10 ml of 293FT
complete medium without antibiotics and incubated for 48 hr at 37°C in 5% C 02.
2.8.3 Harvesting lentivirus
Virus-containing medium was removed, transferred to sterile tubes, and
centrifuged at 3000 rpm for 15 min at 4°C to pellet debris. Cleared supernatant
was filtered through a Millex-HV 0.45 pm PVDF filter (Millipore) and stored at 70°C.
In order to titer lentiviral stocks, CHO-DG44 cells in CHO complete
medium were plated in 6-well plates and incubated at 37°C in 5% C 02 until ~50%
confluent. Serial dilutions from 10~2 to 10"6 of lentiviral stocks (LvASAApoE and
LvGFPApoE) were prepared by diluting stock in CHO complete medium. Medium
was removed from wells and diluted lentivirus was added to wells containing
CHO cells. A mock transfection was also set up with the omission of lentivirus.
Hexadimethrine bromide (Polybrene®, Sigma) was added to each well to a final
concentration of 6 pg/ml and plates were gently swirled to combine. Plates were
incubated overnight at 37°C in 5% C 02.
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The following day, medium containing virus was removed and replaced
with fresh, complete CHO medium containing 3 pg/ml blasticidin. Cells were kept
under selective pressure until all cells in mock transfected wells had died.
Cells were fixed with the addition of 4% paraformaldehyde (PFA) and
incubated for 5-10 min at room temperature. PFA was removed and cells were
washed with phosphate-buffer saline (PBS). PBS was removed and 100 pi of
crystal violet solution was added to each well, incubated for 10 min at room
temperature, and removed. Cells were washed twice with PBS. Colonies were
counted and titer was determined.
2.9 Transducing CHO cells with lentivirus
CHO cells were seeded into 6-well plates with complete CHO medium
and incubated at 37°C in 5% C 0 2 until ~70% confluent. Medium was removed
and replaced with 1 ml of 1/10 dilute lentivirus in complete medium. A mock
transfection was included with the addition of medium only. Hexadimethrine
bromide (Polybrene®, Sigma) was added to each well to a final concentration of
6 pg/ml and plates were gently swirled to combine. Plates were incubated
overnight at 37°C in 5% C 02. Medium was replaced every 48-72 hr with fresh
complete CHO medium supplemented with 3 pg/ml Blasticidin until antibioticresistant colonies were firmly established.
Control cell lines expressing either ASAV5 or GFP were used in the
assessment of protein expression and uptake experiments. These CHO-DG44
cell lines, supplied by this laboratory, were transduced with lentiviral stock
derived from either pLenti6.3-v5GW-asaV5 or pLenti6.3-v5GW-GFP.
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2.10 Collection of fusion proteins
To decrease the amount of interference encountered by the presence of
albumin while purifying protein, all transduced CHO cell lines (transduced cell
lines expressing ASAV5, GFP, ASAApoE, and GFPApoE) were weaned into
serum-free medium (HyClone® SFM4CHO-A™, ThermoScientific) supplemented
with 4 mM L-glutamine (Gibco), 1 X Anti-Anti (Gibco), and 10 X HT media
supplement (Sigma Aldrich). Ammonium chloride (5 pM) and 1X InsulinTransferrin-Selenium-A Supplement (Gibco) were added to serum-free medium
in order to maximize GFP-ApoE secretion and inhibit its degradation (64-66).
Media was collected from transduced CHO cell lines every 48-72 hr.
Upon collection, media was centrifuged at 1,000 x g for 5 min at 4°C and filtersterilized through either 0.2 pm sterile syringe filters (VWR) or Nalgene® filter
units. Media was pooled and stored at -20°C. Concentration of proteins was
performed at4°C using Amicon® Centrifugal Filter Devices (Millpore Corp.).
Proteins were kept on ice between steps. Analysis of enzyme activity was done
with each step of purification using the protocol as listed in Section 2.5.3.
ASAV5, ASAApoE, TfASAV5 proteins were purified using fast
performance liquid chromatography (FPLC) with the AKTApurifier™ system (GE
Healthcare) at4°C controlled by UNICORN™ software.
2.10.1 Desalting
Media containing ASAV5, ASAApoE, or TÍASAV5 was concentrated ~25
fold as noted previously and loaded directly onto a Sephadex-packed desalting
column (HiPrep 26/10 Desalting, Amersham Biosciences) for buffer exchange
into 20 mM Tris-HCI, pH 8.0 (Invitrogen) unless otherwise noted. The column
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was equilibrated with 2 column volumes (CV) of 20 mM TrisHCI, pH 8.0, and
proteins eluted with 3 CV of the same buffer. Flow rate was 7.5 ml/min.
2.10.2 Blue sepharose chromatography
As per 2.10.1, medium containing ASAV5, ASAApoE, or TfASAV5 was
desalted into buffer with the following change: the buffer used for the exchange
was 20 mM sodium phosphate, pH 7.0.
Following buffer exchange, up to 10 ml of desalted solution was applied
to a blue sepharose column (HiTrap™ Blue HP, Amersham Biosciences)
equilibrated with 5CV of Buffer A (20 mM sodium phosphate, pH 7.0). This
column contains Cibacron Blue F3G-A, an aromatic anionic ligand that binds
albumin by electrostatic and/or hydrophobic interactions. The column was
washed with 5 CV of Buffer A and the flow-through was collected. Bound
proteins were eluted with 5 CV of elution buffer (Buffer A with 2M NaCI, pH 7.0).
The flow-through fractions were then applied to the desalting column (2.10.1) for
buffer exchange to 20 mM Tris-HCI for further purification. The flow rate was 2.5
ml/min. The collected solutions were measured for enzyme activity and protein
(absorbance 280 nm).
2.10.3 ConA sepharose 4B chromatography
As per 2.10.1, medium containing ASAV5, ASAApoE, orTfASAV5 was
desalted into buffer with the following change: the buffer used for the exchange
contained 20 mM Tris-HCI, 0.5 M NaCI, 1 mM MnCI2, 1 mM CaCI2, pH 7.4.
Up to 10 ml of the desalted solution was loaded onto a ConA sepharose
4B column (HiTrap™ ConA 4B, Amersham Biosciences) equilibrated with 5 CV of
Buffer A (20 mM Tris-HCI, 0.5 M NaCI, 1 mM MnCI2, 1 mM CaCI2, pH 7.4.) The
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desalted solution was applied 1 ml at a time with a flow rate of 0.25 ml/min with a
5 min pause between each ml applied to allow proteins to bind. The column was
washed with 2 CV of Buffer A and the flow-through was collected. Bound
proteins were eluted at a flow rate of 0.25 ml/min with 10 CV of elution buffer
(Buffer A with 0.4 M methyl-a-D-mannoside, pH 7.4) by applying the first 2 CV of
elution buffer followed by incubation for 30-60 min to allow the elution buffer to
displace bound proteins. The remaining 8 CV of elution buffer was applied to
displace proteins. Proteins that were tightly bound and would not elute under
these conditions were stripped off of the column with 15 CV of 0.1 M borate
buffer (pH 6.5) followed by regeneration of the ConA column with 10 CV of
regeneration buffer (20 mM TrisHCI, 0.5 M NaCI, pH 8.5).
2.10.4 DEAE-cellulose chromatography
Up to 10 ml of desalted solution was loaded onto a DEAE column
(HiPrep DEAE FF 16/10 column, Amersham Biosciences) equilibrated with 5 CV
of Buffer A (20 mM TrisHCI, pH 8.0) and washed with 3 CV of the same buffer.
Proteins were eluted via a linear gradient of NaCI (0.1 M to 0.46 M in Buffer A)
over 5.75 CV. Any proteins still bound to the column were flushed with 3 CV of
1.0 M NaCI in Buffer A and the column was re-equilibrated with 3 CV of Buffer A.
The flow rate was 2.5 ml/min. Fractions were collected and measured for enzyme
activity and absorbance (280 nm) using the method outlined in Section 2.5.3.
2.10.5 Gel filtration chromatography
DEAE fractions having enzyme activity were pooled and concentrated (~
15 fold). Up to 250 pi of concentrated protein was loaded onto a sizing column
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(Superdex® 200 10/300 GL, Amersham Biosciences) equilibrated with 3 column
volumes of 20 mM Tris-HCI, pH 8.0, and eluted for 2 column volumes in the same
buffer using a flow rate of 0.200 ml/min. Fractions were collected and measured
for enzyme activity and protein (absorbance 280 nm). Fractions with enzyme
activity were pooled and specific activity was calculated following the outline in
Section 2.5.3.
2.11 Analyzing fusion proteins
2.11.1 Enzyme activity
The enzyme activity of ASAApoE, TfASAV5, and ASAV5 was calculated
using the protocol listed in section 2.5.3. Protein concentration was determined
using the Bradford method (67) (Bio-Rad) using bovine IgG standards. The
amount of specific activity was expressed as nmol p-NCS cleaved/hr/pg protein.
2.11.2 Gel electrophoresis
SDS-PAGE was performed according to Laemmli, 1970 (68). Briefly,
samples containing 10 pg of protein were diluted in dH20 to 20 pi and added to
non-reducing lane marker sample buffer (5X, Pierce) containing 0.125 M
dithiothreitol (DTT). After heating for 5 min at 95°C, samples were subjected to
electrophoresis in 12% Precise™ precast polyacrylamide gel (Pierce) using
BupH™ Tris-HEPES-SDS running buffer. Proteins were silver-stained using
GelCode™ SilverSNAP® Stain Kit (Pierce) following manufacturer’s protocol.
Using reagents supplied with this kit, the gel was rinsed with deionized water
(dH20) after electrophoresis and fixed for 30 min in 30% ethanol, 10% glacial
acetic acid. Following fixing, the gel was washed in 10% ethanol and then
washed in dH20. The gel was exposed to a sensitizing solution, rinsed in dH20
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and transferred for 30 min to stain solution. After a brief wash step in dH20,
developer solution was added and removed once protein bands appeared (2-3
min). To stop the developer, the gel was incubated in 5% acetic acid. Images of
gels were captured using the BioRad Gel Doc UV-Transilluminator Imaging
System and annotated and analyzed using Quantity One® 4.6.1 quantitation
software.
2.11.3 Analyzing fluorescence
To detect eGFP expression, live transduced CHO cells expressing
GFPApoE and GFP were assessed using fluorescence microscopy. All images
were obtained using a Leica DMIRB fluorescence microscope equipped with a
Qlmaging Retiga 1300 camera and processed with ImprovisionOpenlab software.
2.11.4 Glycosylation
To assess glycosylation of TfASAV5 and ASAApoE fusion proteins and
ASAV5 proteins, proteins were incubated with peptide-N4-(acetyl-pglucosaminyl)-asparagine amidase N-Glycosidase F (PNGase F, New England
Biolabs), an amidase that cleaves the link between asparagine residues and Nacetylglucosamine of N-linked glycoproteins. Apo-transferrin was used as a
positive control. Briefly, 15 pg samples of each fusion protein and apo-transferrin
were denatured withlX denaturing buffer (New England Biolabs) for 10 min at
100°C. After the addition of 1% NP40 and 1X reaction buffer (50 mM sodium
phosphate, pH 7.5), 1000 units of PNGase F were added and the mixture
incubated at 37°C for 1 hr. Samples were loaded onto 12% polyacrylamide
precast gels (Precise, Pierce) and electrophoresed, silver-stained, and visualized
as outlined in 2.11.1.
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2.12 Generating an

in v itro

blood brain barrier

2.12.1 Propagation o f bEND3 cells
An immortalized murine brain endothelial cell line, bEND3 cells
(ATCC#CRL-2299), was a generous gift from Dr. Gediminas Cepinskas at the
Centre for Critical Illness Research, Lawson Health Research Institute. bEND3
cells were maintained in modified DMEM (Dulbecco’s Modified Eagle’s Medium,
10% FBS, 1X Pen-Strep). To prepare flask surfaces for cells, T-75 cm2 flasks
were incubated for at least 20 min with a 1/20 dilution of rat tail collagen, type I
(Sigma) at room temperature which was subsequently removed prior to seeding
bEND3 cells. Medium was replaced every 48-72 hr.
2.12.2 Growth of bEND3 monolayers
bEND3 cells were grown in monolayers on cell culture inserts to form an
in vitro blood brain barrier. These monolayers have polarity with the top of the
surface representing the apical side and the bottom surface representing the
basolateral side (69). To assess the effectiveness of these barriers, the
transendothelial electrical resistance (TEER) across monolayers was measured
and used in conjunction with permeability studies performed using bovine serum
albumin conjugated to Alexa Fluor® 488 (BSA488, Invitrogen) to determine
paracellular passage across the confluent bEND3 monolayers.
bEND3 cells monolayers were grown on cell culture inserts with 3.0 pm
pores (BD Falcon, BD Biosciences) that were coated with collagen as noted
previously. Pre-warmed modified DMEM (600 pi) was added to each well of a
24-well tissue culture plate (BD Biosciences). Collagen-coated inserts were
aseptically placed into wells and bEND3 cells diluted in 200 pi pre-warmed

modified DMEM w ere added to each insert. Cells w ere incubated at 37°C in 5%

C 02 until confluent.
2.12.3 Measuring transendothelial electrical resistance across the
monolayer
To determine the resistance across confluent bEND3 monolayers grown
on permeable supports, TEER measurements in ohms (Q.) were taken using an
epithelial voltohmmeter (EVOM2, World Precision Instruments) using an
EndOhm-6 chamber. Prior to measuring resistance, the resistance across the
tissue culture membranes without the presence of cells was measured to
establish the blank reading. The value of this blank was subtracted from
resistance readings across monolayers to determine true tissue resistance.
TEER readings were taken prior to any manipulations (T0) as well as after
incubation was completed (Ti 6) to evaluate any significant changes in resistance,
indicating changes in permeability (70).
2.12.4 Assessing paracellular transport of BSA
Prior to assessing the passage of BSA across a monolayer, a system was
set up to ensure that BSA488 was able to move through an insert without any
cells. Modified DMEM (600 pi) was added to each well of a 24-well plate and a
cell culture insert was aseptically added. BSA488 diluted in modified DMEM (200
pi total volume) was added to the culture insert and the system was incubated at
37°C in 5% C 02. Samples were taken from both the insert and well at different
time points and were fluorometrically scanned with an excitation/emission
wavelength of 497/520 nm using a multimode microplate reader (Varioskan™,

Thermo Electron Corp.) controlled by Skanlt® software, version 2.2. to assess
the diffusion of BSA488 over time.
To ascertain if the bEND3 monolayers represent relatively impermeable
barriers, medium from the apical side of confluent cells was replaced with 50 pi of
1.0 pg/pl BSA488 in 150 pi modified DMEM and incubated for 16hr at 37°C in 5%
C 02. Following incubation, media from both apical and basolateral sides of
monolayers were collected and fluorometrically scanned. Any background
fluorescence was subtracted and the percentage of BSA488 passing through the
barrier was calculated.
2.13 Uptake o f LDLR-binding fragment of ApoE
The ability of the LDLR-binding fragment of ApoE to be taken up by
bEND3 cells was assessed by comparing the fluorescence of bEND3 cells
incubated with either GFP or GFPApoE for 23 hr. Lysate from CHO cells
expressing either GFP or GFPApoE was assessed as was medium collected
from GFPApoE-expressing CHO cells. The GFPApoE-expressing CHO cells had
been incubated with or without ammonium chloride (5 pM) and 1X InsulinTransferrin-Selenium-A Supplement (Gibco). Briefly, 1 p-Slide V I04 ibiTreat cell
microscopy chambers (ibidi, Germany) were incubated with collagen for 20 min to
prepare the surface for bEND3 cells. Excess collagen was removed and bEND3
cells suspended in pre-warmed modified DMEM were added. The chambers
were incubated at 37°C in 5% C 02for 90 min and modified DMEM medium was
added to fill chamber halfway and cells were incubated until confluent.
When cells reached confluence, the medium was removed and 60 pi
each of protein and modified DMEM were added. Cells were incubated at 37°C in
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5% C 02 overnight and assessed for fluorescence. Representative images were
collected in a Zeiss Axiovert 200M fluorescence microscope using AxioVision 4.6
software with the appropriate filter sets.
2.14 Passage of fusion proteins through

in v itro

blood brain barrier

To assess the passage of fusion proteins, ASAApoE and TfASAV5,
across in vitro blood brain barriers, bEND3 cells were grown to confluence on cell
culture inserts in a 24-well plate as noted previously. TEER readings were taken
across each insert (T0) prior to manipulations. The fusion proteins, TfASAV5 and
ASAApoE, as well as the control protein, ASAV5, were diluted in modified DMEM
and matched for enzyme activity. The existing medium was removed from each
insert (apical side), the diluted proteins were applied to the apical side of the
monolayers, and cells were incubated for 16hr at 37°C in 5% C 02. Following
incubation, the media from both the apical and basolateral sides of the
monolayers were collected and assessed for arylsulfatase A activity and the
percentage of enzyme activity passing through the monolayer was calculated.
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Chapter 3 - Results
PART 1 LENTIVIRAL VECTOR PREPARATION
3.1.1 Polymerase chain reaction
The first step in the construction of fusion proteins was the generation of
att-flanked PCR products by amplifying target DNA with primers containing att
sites. The 17-amino acid sequence of murine cDNA from C57B16 mice
corresponding to the LDLR-binding region of ApoE was amplified and yielded
PCR fragments corresponding to the expected length of 115 bp. Amplification of
V5-epitope tagged full-length ASA from pl_enti6.3-v5GW-asaV5 and of eGFP
from peGFP-N1 yielded fragments corresponding to the expected lengths of 1654
bp and 781 bp, respectively (Figure 3.1).
3.1.2 Creating entry clones
Purified PCR products were used in BP recombination events that inserted
the DNA of interest into donor vectors to generate entry clones. These clones
were subsequently used to transform One Shot® Machl ™ T1R Competent
E.coli. Transformed cells grew in the presence of kanamycin, indicating
successful uptake of target DNA in conjunction with the displacement of the cccfB
gene that inhibits cell growth (see Chapter 2, Figure 2.4). Entry clone DNA
(pDNA) was miniprep isolated from transformed colonies and sequenced to verify
accuracy in BP recombination.
Following sequencing, pDNA was midiprep isolated from colonies and the
quality and quantity of the entry clones were analyzed by spectrophotometry. For
all midiprep-isolated pDNA, the absorbance ratio 260/280 was 1.91-1.94 and the
absorbance ratio 260/230 was 2.2-2.3, indicating relatively pure DNA. The
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Figure 3.1 Gel electrophoresis of PCR amplicons. DNA was PCR-amplified with
primers designed with specific
att-sites and purified for use in do
recombination events. N-ASAV5 and N-eGFP PCR products were PEG-purified
and C-ApoE amplicons were gel purified from 4% agarose. Analysis of N-ASAV5
amplicons yielded fragments with expected size of 1654 bp (a), N-eGFP
amplicons returned fragments with the expected size of 781 bp (b) and C-ApoE
amplicons generated fragments of 115 bp (c). N-ASAV5 and N-eGFP products
were visualized on 1.2% agarose (FlashGel® system, Lonza). C-ApoE amplicons
were visualized on 4% agarose stained with ethidium bromide.

concentration of entry clones was determined as follows: pNASA, 330 ng/pl;
pNeGFP, 247 ng/pl; and pCApoE, 121 ng/pl.
3.1.3 Creating expression clones using pcDNA 6.2/V5-DEST vectors
Entry clones were used in LR recombination events to simultaneously
transfer two DNA elements into pcDNA 6.2A/5-DEST destination vectors to
generate expression clones. pNASA and pCApoE were transferred together to
produce pASAApoE expression clones and pNeGFP and pCApoE were
transferred into the destination vector to create pGFPApoE expression clones.
Following the LR reaction, expression clones were transformed into One Shot®
Machl ™ T1R Competent E. coli. Plasmid DNA was miniprep-isolated and
sequenced to verify each DNA element was inserted accurately (Figure 3.2).
Transformed cells were positively selected in the presence of carbenicillin and
pDNA was midiprep-isolated. The quality and quantity of the entry clones were
analyzed by spectrophotometry. For midiprep-isolated pDNA, the absorbance
ratio 260/280 was 1.88-1.91 and the absorbance ratio 260/230 was 2.19-2.25.
The concentration of expression clones was determined to be 802 ng/pl for
pASAApoE and 478 ng/pl for pGFPApoE.
3.1.4 Transfection of CHO cell lines with pASAApoE and pGFPApoE
Prior to transfection, pASAApoE and pGFPApoE and control vectors,
pLvASAV5 and pLvGFP were linearized using restriction enzymes and yielded
the expected fragments of ~8.5 kb for pLvGFP, ~9.0 kb for pLvASAV5, ~6.0 kb
for pGFPApoE, and ~7.0 kb for pASAApoE (Figure 3.3).
Linearized plasmids were ethanol precipitated and analyzed for quality and
quantity by spectrophotometry. The ratio of absorbance 260/280 (nm) ranged
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Figure 3.2 DNA sequences of pcDNA6.2V5-DEST expression clones generated. DNAfrom two entry clones
were simultaneously inserted into the destination vector, pcDNA6.2/V5-DEST. Tracings indicate proper insertion
of DNA elements in the pASAApoE (top) and pGFPApoE (bottom) expression vectors. Boxes on tracings
enclose the end of either the ASAV5 or eGFP sequences as well as the entire ApoE fragment.
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Figure 3.3 Linearization of fusion constructs and control plasmids. Plasmids to
be used in transfection experiments were linearized using restriction enzymes.
Control plasmids pLvGFP (lane 3) and pLvASAV5 (lane 5) were cleaved with
Sspl to yield approximately 8.5 kb and 9.0 kb fragments, respectively. pGFPApoE
(lane 7) and pASAApoE (lane 9) were cut with Sapl to generate approximately 6
kb and 7 kb fragments, respectively. Lane 1 contains molecular weight markers.
Lanes 2,4,7,8 contain uncut plasmids pLvGFP, pLvASAV5, pGFPApoE, and
pASAApoE, respectively. Fragments were electrophoresed on 0.8% agarose gel
and visualized with ethidium bromide.
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between 1.91-1.97 and absorbance 260/230 (nm) ranged between 1.00-1.48.
The concentration of linearized plasmid was as follows: pLvGFP, 126 ng/pl;
pLvASAV5, 154 ng/pl; pGFPApoE 84 ng/pl; and pASAApoE, 148 ng/pl.
CHO cells were transfected with linearized plasmids using lipofectamine
and after 48 hr, were placed under selective pressure using 3 pg/ml blasticidin in
medium. After 11 days, no non-transfected (mock transfected) cells were viable.
3.1.5 Detection of recombinant fusion proteins expressed in transfectants
3.1.5.1 Transient transfectants
Within 48 hr of performing the transfections, medium was collected for
enzyme assays and cells expressing GFP and GFPApoE were assessed via
fluorescence microscopy. GFP was distributed throughout the entire cell but
GFPApoE appeared to be localized in more discrete areas of the cells (Figure
3.4). Also, fewer cells expressed GFPApoE compared to the number of cells
expressing GFP and the cells were morphologically different with more rounding
of the GFPApoE cell line (data not shown).
Enzyme activity in medium collected from transiently transfected CHO
cells was compared to the endogenous enzyme activity in naive CHO cell
medium. Assays were performed in duplicate for 48 hr at 4°C. Enzyme activity
was calculated by dividing Abs516 reading by the nanomolar extinction
coefficient for pNCS (0.012) and expressed in nmol/hr/ml. There was a 7.6-fold
increase in enzyme activity expressed as nmol/hr measured in medium collected
from cells transfected with pLvASAV5 and greater than a 5.5-fold increase in
enzyme activity (nmol/hr) in medium from cells transfected with pASAApoE
compared activity in medium from in naive CHO cell (Figure 3.5)

Figure 3.4 Fluorescence in transient transfectants. CHO cells were assessed 48
hours after transfection for expression of GFP and GFPApoE. Images were
taken at 200X magnification with a Leica DMIRB fluorescence microscope with a
Qlmaging Retiga 1300 camera using appropriate filters. CHO cells were
transfected with control plasmid, pLvGFP (i) and the expression clone,
pGFPApoE(ii).
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Enzyme Activity in Transient
Transfectants
14 -

CHO naïve

pASAApoE

pLvASA

Transfected Cell Line Assessed
Figure 3.5 Enzyme activity in transient transfectants. Medium from nontransfected (naive) cells and cells transiently transfected with control plasmid,
pLvASA and the expression clone, pASAApoE was assessed 48 hours after
transfection for enzyme activity. Each cell culture was grown to similar levels of
confluence prior to the assessment and assays were performed at 4°C for 48 hr.
Samples were analyzed spectrophotometrically using a multimode microplate
reader (Varioskan™, Thermo Electron Corp.) and absorbance values (516 nm)
converted nmol/hr/ml activity.
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3.1.5.2 Stable transfectants
Once stable transfectants were established, medium was collected and
assayed for enzyme activity and cells expressing fluorescent proteins were
assessed using fluorescence microscopy.
Under fluorescence microscopy, stable transfected CHO cells expressing
either GFP or GFPApoE could be visualized. The number of cells expressing
protein was significantly lower in the GFPApoE cell line. These cells appeared
smaller and typically had a more rounded morphology similar to that seen in the
transiently transfected cells (Figure 3.6).
Enzyme activity in stable transfected CHO cells was assessed as
described in the subsection above with some minor changes: assays were done
in quadruplicate over 72 hr at 4°C. The enzyme activity was 1.94 nmol/hr/ml in
medium from cells transfected with pASAApoE and 477.43 nmol/hr/ml in medium
collected from cells transfected with pLvASAV5 compared to enzyme activity of
0.31 nmol/hr/ml in medium collected from CHO cells not expressing ASAV5
(Figure 3.7).
3.1.6 Generating lentiviral expression plasmid
To increase the stability and expression levels of fusion proteins, lentiviral
expression plasmids were generated using the entry clones created previously in
section 3.2. pLvASAApoE and pLvGFPApoE expression clones were isolated
from transformed cells and sequenced to verify each DNA element was inserted
accurately (Figure 3.8).
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Figure 3.6 Fluorescence in stable transfected cells. Cells were transfected with
plasmids encoding either GFP(a,b) or GFPApoE (c,d). Fluorescence appears
well distributed in GFP-expressing cells (b) but is expressed in discrete areas in
cells expressing GFPApoE (d). Phase contrasts (a,c) and fluorescence images
(b,d) were taken at 200X magnification with a Leica DMIRB fluorescence
microscope equipped with a Qlmaging Retiga 1300.
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Figure 3.7 Enzyme activity in stable transfectants. Medium from CHO cells
without ASA expression, stable transfected cells transfected with control plasmid,
pLvASAV5 and the expression clone, pASAApoE was assessed for enzyme
activity. Assays were performed at 4°C for 72 hr. Samples were analyzed
spectrophotometrically using a multimode microplate reader (Varioskan™,
Thermo Electron Corp.) and absorbance values (516 nm) converted to nmol/hr/ml
activity.
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Figure 3.8 DNA sequences of lentiviral-based expression clones, pLvASAApoE and pLvGFPApoE. DNAfrom two
entry clones was simultaneously inserted into the destination vector. pLenti6.3/V5-DEST. Tracings indicate proper
insertion of DNA elements in the pLvGFPApoE (top) and pLvASAApoE (bottom) expression vectors.
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3.1.7 Restriction enzyme analysis of pLenti
Analysis of pLenti DNA digested by A flll and Xhol appeared to yield the
expected fragments of 3600 bp, 3175 bp, and 1725 bp for pLvGFPApoE and
3750 bp, 3625 bp, 1725 bp, and 198 bp for LvASAApoE (Figure 3.9). The quality
and quantity of the expression clones were analyzed by spectrophotometry. The
absorbance ratio 260/280 was 1.92 for both clones and the absorbance ratio
260/230 was 2.28-2.30. The concentration of expression clones was determined
to be 835 ng/pl for pLvASAApoE and 761 ng/pl for pLvGFPApoE.
3.1.8 Lentivirus production
pLvASAApoE and pLvGFPApoE were each cotransfected with a viral
packaging mix into the 293FT producer line, producing replication incompetent
lentiviral stocks. The titer of each lentivirus was determined and the titer was
determined to be 5.5 x 105 TU/ml for LvASAApoE and 3.4 x 105 TU/ml for
LvGFPApoE (Figure 3.10).
3.1.9 Transducing CHO ceils with lentivirus
CHO cells were transduced with either LvASAApoE or LvGFPApoE with a
multiplicity of infection (MOI) of ~1 and a mock transfected set of cells was
included. Cells were placed under selective pressure using 3 pg/ml blasticidin
and after 13 days no mock transfected cells were viable.
The medium from confluent ASAApoE-transduced cells was collected 24
hr after transduction and exhibited enzyme activity of 169 nmol/hr/ml. Compared
to the activity in stable transfectants (1.9 nmol/hr/ml), transduced cells
demonstrated an 80-fold increase in enzyme activity (Figure 3.11).
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Figure 3.9 Restriction digestions of lentiviral-based plasmids (pLvDNA). To verify
that no rearrangement had occurred in the LTR regions of plasmid, pLvASAApoE
and pLvGFPApoE were digested with endonucleases Xho\ and AflW. Digestion of
pLvASAApoE (lanes 2, 4) indicates expected bands at -3750 bp, -3635 bp,
-1725 bp, and -198 bp. Undigested plasmid is shown in lanes 3 and 5. Digestion
of pLvGFPApoE (lanes 7, 9) indicates expected bands of -3600 bp, -3175 bp,
and -1725 bp. Undigested pLvGFpApoE plasmid is shown in lanes 8, 10. Lanes
1,6, and 11 represent molecular weight markers. Aliquots of digested pLvDNA
were electrophoresed on 0.8% agarose gel and visualized with ethidium bromide.
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Figure 3.10 Titer of lentiviral stocks. Titers were determined using CHO cells
transduced with 10-fold serial dilutions of lentiviral supernatant (10'2 to 10'6
dilutions) or untransduced (mock) cells. Cells were placed under Blasticidin
selection (3 pg/ml) 48 hr after the transduction (day 2). On day 15, cells were
fixed with 4% PFA and stained with crystal violet. Titer was determined to be 5.5
x 105 TU/ml for LvASAApoE (top) and 3.4 x 105 TU/ml for LvGFPApoE (bottom).
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Figure 3.11 Enzyme activity in transduced vs transfected cells. Media was
collected from CHO cells expressing ASAApoE. Cell lines had either been
transfected with plasmid or had been transduced with replication-incompetent
lentivirus. Cell lines were at similar levels of confluence at the time of harvest and
media was analyzed for enzyme activity using an absorbance wavelength of 516
nm and converted to nmol/hr/ml enzyme activity.
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PART 2 FUSION PROTEIN PURIFICATION AND CHARACTERIZATION
3.2.1 Collection of fusion proteins
The first set of steps in the collection of fusion proteins included the
removal of albumin in conditioned media that contained serum. Therefore,
medium with serum containing secreted ASAApoE was desalted into 20 mM
sodium phosphate (pH 8.0), followed by separation of proteins through a column
containing Cibacron Blue to separate fusion proteins from albumin. The flow
through fractions containing enzyme activity were again applied to a desalting
column, this time to exchange buffer for 20 mM TrisHCI (pH 8,0), followed by
application to an anion-exchange column. The elutate was collected in 1 ml
fractions and analyzed with SDS-PAGE (Figure 3.12), indicating one protein band
that migrated to the expected distance of an approximately 65 kDa protein. This
method of isolating proteins, however, was aborted and transduced CHO cells
were weaned into serum-free medium to eliminate albumin interference.
The second attempt at protein purification used a ConA column to bind the
fusion proteins and separate them from albumin in the condition media that
contained serum. Medium containing secreted ASAV5, TfASAV5, or ASAApoE
was desalted into 20 mM TrisHCI as noted previously and applied to a ConA
column. Under the conditions used, the enzyme-containing proteins were difficult
to elute, stripping the column with 15 CV of 0.1 M borate buffer showed protein
was still trapped in the column. This method was deemed impractical for the
purpose at hand.
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Figure 3.12 Purification of ASAApoE using Cibacron blue F3G-A. Purifying the fusion
proteins was complicated by the presence of albumin, a protein that is similar in size to
ASA. To remove albumin, samples from cells expressing ASAApoE were applied to a
HiTrap™ Blue HP column (GE Healthcare Life Sciences). The flow-through fractions
containing enzyme activity were applied to a DEAE column. DEAE fractions having
enzyme activity were pooled and analyzed using SDS-PAGE under reducing conditions
with 12% polyacrylamide gel and silver-stained for visualization. Under these
conditions, there is one clear band, indicating that the protein is ~65 kDa, the expected
size of ASAApoE.
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The third protocol for purification was used for collection of fusion proteins
after the cells were weaned into serum-free media. Serum-free medium
containing secreted proteins (crude medium) was collected and concentrated ~
20-fold. Concentrated medium was loaded onto a desalting column to exchange
medium for 20 mM TrisHCI (pH 8.0), followed by separation of proteins in an
anion-exchange column. The eluate was collected in 1 ml fractions. To further
purify ASAV5 and ASAApoE, DEAE fractions containing enzyme activity were
pooled, concentrated, and applied to a sizing column. Eluted fractions were
collected in 0.48 ml fractions and the fractions with enzyme activity were pooled
(Figures 3.13, 3.14, 3.15).
3.2.2 Analyzing fusion proteins
3.2.2.1 Enzyme activity
All fractions collected from Part 2, section 3.2.1 were measured for ASA
activity, absorbance (280 nm) and total protein content. The specific activity
(S.A.) in nmol/hr/pg protein was calculated for each step in the purification
process and the purification index assessed. An increase in S.A. was noted for
each step in the purification process with the exception of DEAE fractions
collected from the purification of ASAApoE. These fractions indicated a decrease
in S.A. when compared to the calculated S.A. of the fractions collected from
desalted media. TfASAV5 fractions collected following elution from the DEAE
column indicated a 3.50-fold increase in specific activity purification from the
crude medium prior, with a S.A. of 58.69 nmol/hr/pg protein. The S.A. of ASAV5
and ASAApoE fractions collected from the gel filtration column was 59.24
nmol/hr/pg protein and 26.34 nmol/hr/pg protein, respectively. There was a 7.30-
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Figure 3.13 Chromatograms from ASAApoE purification. Fast performance liquid chromatography (FPLC) with the
ÁKTApurifier™ system (GE Healthcare) was used for purification. Fractions were monitored for absorbance (280
nm) and recorded in mAu. Media from transduced CHO cells expressing ASAApoE was collected from 75 cm2
flasks every 48-72 hr, filter-sterilized, and pooled. These pooled contents were concentrated and applied to a
desalting column for buffer exchange into 20 mM TrisHCI, pH 8.0 (a). Desalted contents were applied to an anionexchange column and proteins eluted using a linear gradient of elution buffer (20 mM TrisHCI, 1 M NaCI, pH 8.0)
(b). Collected fractions having enzyme activity were pooled, concentrated, and applied to a sizing column.
Collected fractions from the sizing columns that were positive for enzyme activity were pooled and stored at -20°C.
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Figure 3.14 Chromatograms from ASAV5 purification. Fast performance liquid chromatography (FPLC) with the
ÁKTApurifier™ system (GE Healthcare) was used for purification of protein. Fractions were monitored for
absorbance (280 nm) and recorded in mAu. Media from transduced CHO cells expressing ASAV5 was collected
from 75 cm2 flasks every 48-72 hr, filter-sterilized, and pooled. These pooled contents were concentrated and
applied to a desalting column for buffer exchange into 20 mM TrisHCI, pH 8.0 (a). Desalted contents were applied
to an anion-exchange column and proteins eluted using a linear gradient of elution buffer (20 mM TrisHCI, 1 M
NaCI, pH 8.0) (b). Collected fractions having enzyme activity were pooled, concentrated and applied to a sizing
column. Collected fractions from the sizing columns that were positive for enzyme activity were pooled and stored
at -20°C.
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Figure 3.15 Chromatograms from TfASAV5 purification. Fast performance liquid chromatography (FPLC) with the
AKTApurifier™ system (GE Healthcare) was used for purification process. Fractions were monitored for
absorbance (280 nm) and recorded in mAu. Media from transduced CHO cells expressing TfASAV5 was collected
from 75 cm2 flasks every 48-72 hr, filter-sterilized, and pooled. These pooled contents were concentrated and
applied to a desalting column for buffer exchange into 20 mM TrisHCI, pH 8.0 (a). Desalted contents were applied
to an anion-exchange column and proteins eluted using a linear gradient of elution buffer (20 mM TrisHCI, 1 M
NaCI, pH 8.0) (b). Collected fractions having enzyme activity were pooled and stored at-20°C
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fold increase in purification for ASAV5 and 4.89-fold increase in purification for
ASAApoE. (Table III)
3.2.2.2 Gel electrophoresis

Aliquots of ASAV5, ASAApoE, and TfASAV5 from fractions collected
during the purification steps were analyzed by SDS-PAGE and silver stained for
relative size of the protein and for relative purity. The sizing fractions collected
from ASAApoE did not resolve into discrete bands but present as a smear
between 47.7-77.6 kDa. Repeated attempts to resolve the sizing fractions into
discrete bands were unsuccessful. The DEAE fractions collected and pooled from
TfASAV5 resolved as a large, single band with the expected size of 140 kDa.
Assessing the sizing fractions collected from ASAV5, there is one large band
corresponding to the expected 62 kDa band expected and a second, smaller
band resolves at ~ 40 kDa. (Figure 3.16)
3.2.2.3 Analyzing fluorescence

Live transduced CHO cells were analyzed using fluorescence microscopy
to detect the expression of GFP and GFPApoE (Figure 3.17). Transduced CHO
cells expressing GFP-ApoE and GFP were assessed using fluorescence
microscopy to determine the intensity and location of GFP fluorescence.
Whereas GFP appeared to be expressed evenly throughout the cell, GFPApoE
appeared to be more localized within the cell body.
3.2.2.4 Glycosylation

TfASAV5, ASAApoE, ASAV5, and a control protein apo-transferrin (ApoTf)
were incubated with (+) or without (-) PNGase F. Samples of each protein were
loaded on 12% polyacrylamide gels, electrophoresed, and silver-stained. A

Table III Purification of Recombinant Proteins

Protein
ASAV5

TfASAVS

ASAApoE

Step

volum e
In
sample
(m il

Enriched media
Desalting column chromatography
Ion exchange chromatography
Gel Filtration

8.20
4.15
0.55
192

Enriched media
Desalting column chromatography
ion exchange chromatography

10
8.50
4.80

Enriched
Desalting column chromatography
Ion exchange chromatography
Gel Filtration

16.00
9.50
1.20
7.68

Total
Enzyme
A ctivity
(pmol/hr)

;

Specific
A ctivity
(pmol/hr/mg)

59.94

100%
95%
72%
63%

10
15
3.8
7.2

16.79
18.00
59.38

100%
94%
87%

10
11
3.5

5.37.
' 5.98
6.26
26.65

100%
93%
85%
74%

1.0
1.1
1.2
5.0

186
178
135
117

8.32
12.36
3146

363
340
315
391
362
■ 332
289

Y ield1

P urification
Factor2

1Percent yield compares total enzyme activity resulting from each purification step to total enzyme activity in the starting material
2 Purification factor compares specific activity of solution from each purification step to specific activity in the starting material

Figure 3.16 SDS-PAGE analysis of proteins. Aliquots from each step of the purification schema were
electrophoresed in a 12% polyacrylamide gel under reducing conditions and silver stained for visualization.
Samples of ASAApoE in lanes 1a, 1b, 1c represent aliquots from crude media, pooled desalted fractions, and
pooled sizing fractions (respectively). Lanes 2a. 2b. 2c represent aliquots from TfASAVS crude media, desalted
fractions, and DEAE pooled fractions, respectively. Samples of ASAV5 in lanes 3a, 3b. 3c represent samples from
desalted fractions. DEAE pooled fractions, and pooled sizing fractions, respectively. The expected size of
ASAApoE is ~ 65 kDa. ASAV5 is - 62 kDa. and TfASAV5 is expected to be ~ 140 kDa. No clear resolution of
ASAApoE from sizing columns was obtained.
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Figure 3.17 Transduced CHO cells expressing GFPApoE (a) and GFP (b) were assessed using fluorescence
microscopy. Images were obtained at 200X magnification using a Leica DMIRB fluorescence microscope with a
Qlmagmg Retiga 1300 camera Whereas GFP appears to be expressed evenly throughout the cytosol (b),
GFPApoE appears to be more compartmentalized within the cells.
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downward shift in mobility was visible in samples of ApoTf, TfASAV5, and ASAV5
that had been incubated with PNGase F compared to the same proteins not
incubated with PNGase F, indicating the removal of N-linked carbohydrate.
Samples of ASAApoE resolved as a smear, with no discrete bands observed
regardless of the presence or absence of PNGase F. (Figure 3.18)
PART 3 BLOOD BRAIN BARRIER MODEL EXPERIMENTS
3.3.1 Generating an

in vitro BBB

bEND3 cells grew on collagen-coated cell culture inserts in the presence
of modified DMEM. After approximately 48 hr of incubation, cells were of suitable
confluence to assess both the electrical resistance of the monolayer as well as
the ability of proteins to cross the layer.
3.3.2 Measuring transendothelial electrical resistance (TEER) across the
monolayer

To assess resistance across the monolayer over time, measurements
were taken prior to starting any experimentation (To) and upon completion of
experimentation (Ti 6). Readings were corrected for the background resistance
encountered by the cell culture insert (11 Q) and standard deviations calculated.
No significant change in TEER was observed and the average TEER a tT 0 was
53.96+/-3.77 Q and at T i 6 was 52.71 +/-5.58

(Figure 3.19).

3.3.3 Assessing paracellular transport of BSA488

A standard curve was produced comparing the concentration of BSA488
to relative fluorescence units and the slope of the curve was calculated to be
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Figure 3.18 Release of N-linked oligosaccharides by PNGase F. Fusion proteins and a control glycoprotein, apotransferrin (ApoTf). were incubated with (+) or without (-) PNGase F for 1hr at 37°C. Samples were subjected to
12% SDS-polyacrylamide gel electrophoresis and silver-stained for visualization. The control protein displayed a
downward shift in protein mobility after treatment with PNGase F. A similar shift is also seen in PNGase F-treated
TfASAv5 and ASAV5. Samples of ASAApoE did not resolve into discrete bands.
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Figure 3.19 TEER readings across bEND3 monolayers. After 16 hr of exposure
to proteins, there was no significant decrease in TEER readings across bEND3
monolayers. Transendothelial electrical resistance across the monolayer was
measured prior to any manipulation (T0 left) and measured again after 16 hr (Ti6,
right) of exposure to ASAV5, ASAApoE, and TfASAV5. Numbers were corrected
for background resistance and standard deviation calculated. (n=24)
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y = 0.8606x + 28.694. Concentrations between 25-750 pg/ml were measurable
within the curve (Figure 3.20, top).
To ensure that proteins were capable of diffusing through the membrane
of the cell culture inserts, BSA488 was measured for diffusion across the
membrane without a cell monolayer present. Samples were scanned for
fluorescence with excitation/emission wavelengths of 497/520 nm. Over the
period of 6.5 hr, a decrease in fluorescence was measured in the cell culture
insert with a corresponding increase in the well below the membrane (Figure
3.20, bottom). Using the slope of standard curve, RFU readings were converted
to the concentration of BSA488 (mg/ml), indicating that ~20% of the BSA488
diffused across the membrane during the incubation period.
To assess the passage of BSA488 across the bEND3 monolayer, samples
of 50 pg of BSA488 were diluted in modified DMEM and applied to the apical
sides of bEND3 monolayers (n=8). After 16 hr of incubation, the medium was
removed from both the apical and basolateral sides of the membrane and the
passage of protein was calculated. The average RFU/ml on the apical side after
16 hr was 1201.61 +/- 83.48 and on the basolateral side was 39.18 +/- 3.30.
Under these conditions, 3.16% of the BSA488 translocated across the monolayer
(Figure 3.21).
3.3.4 Uptake of LDLR-binding fragment of ApoE
To assess the ability of the ApoE peptide to facilitate uptake of protein into
bEND3 cells, lysate from GFP-expressing CHO cells and lysate and medium
from GFPApoE-expressing CHO cells were applied to bEND3 cells and
incubated for 23 hr. Fluorescence was seen in discrete areas of cells incubated
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Figure 3.20 Bovine serum albumin conjugated to AlexFluor488 (BSA488) was
measured for fluorescence at known concentrations to generate a standard curve
(top). To determine the ability of BSA488 to diffuse through 3.0 pm pores in cell
culture inserts, BSA488 was added to the insert and assessed for changes in
fluorescence in both the insert and the well below the membrane (bottom).
Fluorescence was measured at excitation/emission wavelengths of 497/520 nm.
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Figure 3.21 The passage of BSA488 was assessed with application of 50 pg of
the protein to the apical side of a bEND3 monolayer. After 16 hr, samples were
taken and assessed for fluorescence from both the apical (left) and basolateral
side (right) of the monolayer. Fluorescence was measured with
excitation/emission wavelengths of 497/520 and was corrected for background
fluorescence. (n=8)
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with GFPApoE. There was no significant uptake in cells incubated with GFP and
no fluorescence was seen in naive bEND3 cells (Figure 3.22).
3.3.5 Passage of fusion proteins through

in v itro

blood brain barrier

To assess the passage of the fusion proteins, ASAApoE and TfASAV5, as
well as ASAV5 across the bEND3 monolayer, between 2000-2800 nmol/hr of
each protein was diluted in modified DMEM and applied to the apical side of a
bEND3 monolayers followed by incubation for 16 hr. TEER readings were taken
across each monolayer before the proteins were applied and after the 16 hr
incubation period and were consistent at both time points (Figure 3.23 a).
Medium was removed from both the apical and basolateral sides of the
monolayer and assessed for enzyme activity. The total enzyme activity in media
from the apical side of the monolayers were: TfASAV5, 388.0 nmol/hr; ASAApoE,
214.5 nmol/hr, and ASAV5, 77.2 nmol/hr. For total enzyme activity in medium
from the basolateral side of the monolayers were: TfASAV5, 2.9 nmol/hr;
ASAApoE, 3.5 nmol/hr; ASAV5, 2.0 nmol/hr. The percentage of enzyme activity
that passed through the bEND3 monolayer was 0.74 % (+/-0.02) for TfASAV5,
1.59 % (+/-0.09) for ASAApoE, and 2.58 % (+/-0.11) for ASAV5 (Figure 3.23 b).
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Figure 3.22 Uptake of fluorescent proteins in bEND3 cells. bEND3 cells were
incubated for 23 hr without protein (a), with GFP cell lysate (b), and medium
collected from GFPApoE-transduced CHO cells (c,d) and assessed for uptake of
fluorescence. Each image on the left (phase contrast) is from the same field as
the fluorescent image on the right and was visualized using a Zeiss Axiovert
200M fluorescence microscope at 400 X magnification.

TEER across bEND3 monolayer over 16 hr incubation with
protein

Protein Across bEND3 Monolayer after 16 hr incubation

b
Figure 3.23 Passage of fusion proteins across bEND3 monolayers (n=4). (a) Prior to application of proteins to the
apical side of the bEND3 monolayer, TEER readings were taken (To). Following 16 hr of incubation, these readings
were once again measured (Tie), (b) Fusion proteins, TfASAV5 and ASAApoE. as well as ASAV5 and BSA488
were applied to the apical side of bEND3 monolayers. After 16 hr, samples were collected from both the
basolateral and apical sides of the bEND3 monolayer. The enzyme activity (nmol/hr/total volume) was calculated
for medium collected from cells incubated with TfASAVS, ASAApoE, and ASAV5. Relative fluorescence units were
measured from samples collected from cells incubated with BSA488. The percentage of proteins located on the
basolateral side was calculated
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Chapter 4 - Discussion and Conclusions

4.1 Summary of project
This project consisted of three main objectives:
1. Construction of ASAApoE and GFPApoE fusion proteins
2. Assessing the expression of ASAApoE, TfASAV5, and ASAV5 in a
eukaryotic expression system
3. Delivery of fusion proteins having ASA activity through an in vitro
blood-brain barrier
4.1.1 Successful construction of ASAApoE and GFPApoE
In this thesis, two different fusion proteins, ASAApoE and GFPApoE were
generated. The LDLR-binding domain of apoE was fused to the C-terminus of the
gene sequence for ASAV5 to preserve the signal sequence in the ASAV5 pre
protein for targeting to the mannose-6 phosphate pathway. The proteins were
expressed by CHO cells transduced with lentiviral-based expression vectors. This
observation is based on the following facts:
a) Lentiviral expression vectors were digested using restriction enzymes and
displayed the expected digestion patterns, indicating that proper
recombination into the vector had occurred (Figure 3.9).
b) The vectors were sequenced and the sequences were analyzed (Figure 3.8).
The vectors contained either the full-length ASA-V5 gene or the full-length
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eGFP gene fused with a 21 nucleotide linker to the 17 amino acid fragment of
ApoE at the C-terminus with the correct orientation (Figure 3.8)
c) After using the expression vectors to generate lentiviral stock, CHO cells were
transduced and analyzed for fusion protein expression. GFPApoE-expressing
CHO cells displayed fluorescence (Figure 3.17) and ASAApoE-expressing
CHO cells had a specific activity of 26 pmol/hr/mg protein (Table III)
4.1.2 Expression of ASA-fusion proteins in eukaryotic expression systems
The characteristics of proteins ASAApoE, ASAV5, and TfASAV5
(previously generated by Danielle Croucher) were assessed for size, enzyme
activity, and glycosylation state.
a) Sizing and enzyme activity
While isolating an enzyme, each purification step should result in an
increase in enzyme S.A. with a Corresponding decrease in the amount of total
protein. Aliquots of fractions collected at each step were electrophoresed under
denaturing conditions to assess purity.
The proteins recovered had: S.A. of 26 and 74% yield for ASAApoE; S.A.
of 59 and 63% yield for ASAV5; and S.A. of 59 and 87% yield forTfASAV5
(Table III). SDS-PAGE analysis of each fraction shows protein bands resolved on
the gel to distances corresponding to the expected size of the fusion proteins
(Figure 3.16). The smearing pattern seen in the ASAApoE sizing fractions is
discussed in Chapter 4.2.
b) Glycosylation state
ASA is normally glycosylated and carries high mannose oligosaccharides.
Both ASAV5 and the fusion protein, TfASAV5 appear to be N-glycosylated based
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on a shift in mobility on SDS-PAGE following deglycosylation by PNGase F
(Figure 3.16). Repeated attempts to assess the glycosylation state of ASAApoE
were unsuccessful; however it is important to note that ASAApoE retained
enzyme activity. In order to be active, this protein requires modification of the
amino acid, cysteine-69, to a formylglycine residue (6). This modification occurs
post-translationally and has been shown to likely occur after N-glycosylation (71).
Based on these previous studies, it is likely that ASAApoE is N-glycosylated.
Other experiments could be used to confirm the presence of glycoproteins for
example, treatment with endoglycosidase such as Endo H, performance of SDSPAGE of the protein could be followed by either staining with periodic acid-Schiff
reaction or by lectin blotting using concanavalin A .(72-74)
c) Development o f an

in v itro

blood-brain barrier

For the purpose of these experiments, bEND3 cell monolayers formed
effective blood brain barriers based on the following: the integrity of the
membrane was maintained according to the stability of transendothelial electrical
resistance across the monolayer over a 16-hr period (Figure 3.19); and
approximately 3% of BSA488 applied to the apical side of the monolayer passed
into the basolateral compartment (Figure 3.20). Because the blood brain barrier
does not appear to express any specific transport mechanism for albumin (75),
passage of BSA488 can be assumed to be through leakage between bEND3
cells of the in vitro BBB barrier.
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4.1.3 Delivery of active enzyme through an in vitro blood-brain barrier
Under the conditions used, neither ASAApoE nor TfASAV5 passed
through the bEND3 monolayer at levels higher than the BSA488 baseline (Figure
3.23b). Possible explanations for these results are discussed in Chapter 4.3.
Despite the apparent lack of passage of the fusion proteins, the ApoEfragment did appear to facilitate the uptake of GFP. Fluorescent assessment of
bEND3 cells incubated with either GFP or GFPApoE indicated that those cells
incubated with GFPApoE had taken up the fluorescent protein in a perinuclearlike distribution (Figure 3.22). No fluorescence was seen in cells incubated with
GFP, indicating that the ApoE-fragment may be necessary for uptake.
4.2 Unexpected results and challenges
a) Plasmid transfection of CHO led to low-level expression of proteins
Plasmid transfectants had insufficient levels of expression based on
enzyme activity. To increase expression, lentiviral expression vectors were
generated. This resulted in an over 80-fold increase in enzyme activity (Figure
3 1 1)b) Albumin interfered with purification process
10% FBS was used as a component of the CHO culture medium (Chapter
2.4.1). FBS contains albumin, a 66 kDa protein approximately the same size as
both ASAV5 and ASAApoE and the presence of albumin in harvested media
resulted in interference during the purification process. Initially, media was
desalted and applied to a column containing Cibacron Blue F3G-A which binds
albumin. The flow through collected from this column contained ASAApoE and
the enzyme-containing fractions were desalted and applied to a DEAE column.
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Fractions having enzyme activity were pooled and analyzed using SDS-PAGE
under reducing conditions with 12% polyacrylamide gel and silver-stained for
visualization. Under these conditions, there is one clear band, indicating that the
protein is ~65 kDa, the expected size of ASAApoE (Figure 3.12).
Another approach used to isolate the enzyme away from albumin was the
use of ConA-Sepharose chromatography. The column used contains
concanavalin A (Con A), a protein isolated from the jack bean that binds
molecules containing a-D-mannopyranosyl, a-D-glucopyranosyl and sterically
related residues. After applying the proteins to this column, however, the ASAfused proteins were so strongly bound that elution of enzyme became
impractical. Similar difficulties in eluting ASAV5 from ConA columns have been
encountered by other researchers in this laboratory.
Due to the complications and number of steps required to remove albumin
from the media, a decision was made to wean the CHO cells into a serum-free
medium. The cells were successfully weaned into this medium, retaining enzyme
activity, however the cells became less adherent and more than 70% of cells
were in suspension.
c) ASAApoE resolved in a smear following SDS-PAGE
Several attempts were made to demonstrate that ASAApoE collected from
DEAE-column chromatography and the sizing column were the expected size of
~65 kDa. The resolution of the sizing fractions under reducing conditions was
poor and resulted in smearing (Figure 3.16). It should be noted, however, that
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with the use of cibacron blue column chromatography, the isolated protein was
clearly illustrated to be the correct size (Figure 3.12).
One possible reason for the lack of a discrete protein band could be the
presence of multiple species with different glycosylation states. This is unlikely to
be the problem, however, because the banding did not become tighter following
treatment with PNGase F, which should have removed any existing sugar
moieties and resulted in a single deglycosylated form as seen for TfASAV5 and
ASAV5 (Figure 3.18).
Another reason for the smearing could have been the conditions used for
SDS-PAGE. To address this possibility, different periods of heat-denaturation
were used, fresh DTT was used, and the proteins were rapidly cooled in an ice
and ethanol bath following heat-denaturation. None of these steps resolved this
problem.
Because ASAV5 was purified under the same conditions as ASAApoE and
resolved to a clean band, it is unlikely that the buffers or columns used for FPLC
resulted in smearing. However, elution of ASAV5 and ASAApoE from the DEAE
column requires slightly different concentrations of NaCI (Figures 3.13, 3.14). It is
possible, then, that proteolytic lysosomal enzymes could co-purify with and cause
partial degradation of ASAApoE, resulting in smearing seen on the gels. Due to
time constraints and the fact that active enzyme was collected, attempts were not
made to inhibit proteases present.
It is possible that the protein formed aggregates during the purification
process or in the presence of the SDS. Due to time constraints, different methods
to ensure that the protein was fully denatured were not examined.
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d) Molecular Trojan horses fused to ASA did not transcytose
Under the experimental conditions used, there was no apparent
transcytosis of fusion proteins. However, the fact remains that GFPApoE but not
GFP was taken up by bEND3 cells (Figure 3.22) indicating that the ApoEfragments facilitated uptake of fusion proteins. Several suggestions regarding the
lack of transcytosis of ASAApoE and TfASAV5 are discussed in the next section.
4.3 Possible reasons for lack of successful transcytosis
a) Different Fates of transcytosis
In reduced form, BSA488 is approximately 66 kDa, TfASAV5 is
approximately 140 kDa, while ASAV5 and ASAApoE are approximately 62 kDa
and 65 kDa, respectively. Although there is some evidence that the rate of
receptor-mediated transcytosis is not dependant on the size of the protein(76),
the increasing size of proteins correlate to the percentage of the proteins found
on the basolateral side of the bEND3 monolayer after 16 hr incubation (Figure
3.23).
It should be noted that at pH 7.5, ASA exists as a homodimer with a
molecular weight of ~110 kDa (77) with possible exposure of both N- and Cterminal portions (78). Assuming that the other ASA-fusion proteins also form
homodimers, ASAApoE would be ~120 kDa and TfASAV5 would be ~280 kDa.
Interestingly, if the sizes of the protein dimers are compared to the percentage of
total protein that entered the basolateral compartment, there is a clear decrease
in passage as proteins increase in size (Figure 4.1). It is possible then, thatthe
size of the proteins have an inverse relationship with the rate of transcytosis.
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b) Endocytosis w ithout transcytosis
TfASAV5 and ASAApoE were designed to express a V5 epitope tag to
enable detection of the proteins in bEND3 cells using antibody detection.
Unfortunately, V5 antibodies cross-reacted with the bEND3 cells and the
presence of ASAApoE, ASAV5, and TfASAV5 in these cells could not be
determined (data not shown). As well, bEND3 cells have endogenous levels of
transferrin and ASA, such that antibodies to these proteins are unlikely to
discriminate between native and fusion proteins. It was therefore not possible to
determine the presence of the fusion proteins within the cells and endocytosis of
the fusion proteins could not be ascertained.
c) Competition fo r binding sites
bEND3 cells were grown in complete DMEM medium containing 10%
FBS. Attempts to grow these cells with a lower concentration of FBS resulted in
cells that appeared less adherent and less likely to form appropriate monolayers
(results not shown). For transcytosis experiments, ASAV5, ASAApoE, TfASAV5,
and BSA488 proteins were diluted in bEND3 complete medium and the final
amount of FBS in the diluted samples ranged from 2.5-7.5% (TfASAV5, 2.5%;
ASAApoE, 6.25%; ASAV5 and BSA488, 7.5%). The medium on the basolateral
side of the monolayer contained 10% FBS.
FBS contains both transferrin and LDL and these proteins would likely
have high affinity for binding to available receptors on bEND3 cells and,
therefore, very strong potential to compete with the Trojan horses for binding
sites. To determine the concentration of these proteins in FBS, the average
concentration of LDL and transferrin in 10 different lots of qualified FBS were

99

Size of Protein Affects Passage Across
Monolayer

0

50

100

150

200

250

300

Proposed Size of Protein in System (kDa)
Figure 4.1 Effect of protein size on transcytosis. A comparison of the proposed

size of the proteins that are applied to the in vitro blood brain barrier to the
percentage of that protein entering the basolateral compartment of the barrier
appears to indicate a connection between the size of the protein and the ability to
translocate to the basolateral compartment. This chart assumes that ASAV5,
ASAApoE, and TfASAV5 exist in a dimerized form in solution.
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calculated from published Certificates of Analysis by Invitrogen (79) and
determined to be ~17.06 ± 1.73 mg/dL and 226.82 ± 45.69 mg/dL, respectively.
These concentrations can be roughly converted into nanomolar concentrations
based on the following: bovine transferrin is ~ 76 kDa (80); and the main
component of calf serum LDL is ApoB, a 3 million Da particle. Therefore, the
concentration of TfASAV5 applied to the apical side of the system was ~ 8100
pmol/L and this would be competing with ~ 750 pmol/L serum transferrin. The
concentration of ASAApoE was ~ 8 pmol/L and it would be competing with ~ 3.5
nmol/L of serum LDL.
To out-compete the fusion proteins for binding to ligand, this would require
that the affinity of the TfR for binding to serum transferrin and of LDLR for binding
to serum LDL would remarkably have to be 10-fold and 2000-fold higher than the
affinity for TfASAV5 and ASAApoE, respectively,
d) Reduction in Number of Receptors Available
There are studies available documenting the uptake of transferrin and LDL
by bEND3 cells (82, 83). Although there is little data available to quantity the
number of Tf or LDL receptors available on these cells, the evidence indicates
that receptors are up-regulated when the basolateral compartment of the in vitro
blood brain barrier contains lipoprotein-deficient serum or serum-free medium.
The receptors have also been shown to be up-regulated in in vitro blood barriers
generated from co-cultures of cerebrovascular endothelial cells and astrocytes
(84-86).
The inference from these studies is that the number of receptors available
for the experiments described in this thesis may be reduced due to the presence
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of serum in the basolateral compartment as well as the absence of astrocytes in
a co-culture. Therefore once the available receptors have been fully occupied by
their ligand, increasing the concentration of fusion proteins applied to the system
would not likely increase their rate of uptake (76).
4.4 Future Considerations
Future considerations for uptake experiments across the bEND3
monolayer include the following:
a) In order to isolate the fusion proteins, protease inhibitors should be included in
harvested cell culture medium.
b) To better resolve ASAApoE on SDS-PAGE, the protein samples could be
heated in loading buffer at 60°C for 20 minutes and different denaturants
could be used such as urea. As well, the addition of mild detergents such as
CHAPS or NP-40 to the purification processes may reduce the risk of
aggregation.
c) Cultivation of bEND3 into serum-free medium would reduce the interference
of serum proteins to uptake experiments. This may also result in up-regulation
of receptors on the cell surface.
d) A co-culture of bEND3 cells with astrocytes may also result in a better in vitro
BBB as well as up-regulation of receptors on bEND3 cells.
e) Competition experiments may aid the interpretation of the methods by which
fusion proteins are taken up by bEND3 cells. Quantifiable competition with
either ligand or antibodies specific to receptors should be considered to
optimize the concentration of fusion protein to be applied to an in vitro blood
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brain barrier system. It should also be noted that ASA-containing fusion
proteins may be taken up by M6PR and therefore mannose-6-phosphate can
be used for competition studies as well.
f) In order to study the uptake of fusion proteins in bEND3 cells, fusion proteins
could be generated that incorporate a different epitope tag could be used for
visualization of the fusion proteins in fixed cells.
g) Studies could be undertaken to determine the rate of transcytosis of the
proteins in different time trials.
h) Further studies could determine the effect of the fusion proteins on sulfatide
storage in arylsulfatase A deficient cells.
4.5 Conclusion
In this study, fusion proteins were generated using the LDLR-binding
region of apoE as a molecular Trojan horse bound to full-length ASA. As well, an
in vitro blood brain barrier was produced using an immortalized murine
cerebrovascular endothelial cell line. Under the initial experimental conditions,
transcytosis of fusion proteins was not observed. However, there was evidence
indicating that the apoE peptide was capable facilitating the uptake of fusion
proteins into the BBB cells based on intracellular fluorescence in the cells
exposed to GFPApoE fusion proteins.
The optimal experimental conditions for the use of these fusion proteins
require much more investigation before any conclusions are made regarding their
ability to transcytose the blood brain barrier. Ultimately, the goal of these
experiments is to find an effective treatment for MLD.
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